The Longevity Digest 05/26 - 06/01
I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.
Welcome to The Longevity Digest.
The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.
I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.
Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.
This Newsletter Is Sponsored By Casa de Sante.
Dr Onyx MD PhD’s Insights on this week’s episodes
Longevity Is Becoming Systems Medicine
The clearest signal across The Human Upgrade episodes “Why Are Hackers Microdosing ‘Sex Drugs’ Now?”, “The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele,” and “Combine Creatine With THIS To Fight The Root Cause of Aging | Andrew Salzman” is that longevity care is shifting from generic prevention to systems engineering: regulate autonomic tone, vascular perfusion, mitochondrial output, and gut-barrier integrity, then confirm the response with smarter biomarkers instead of waiting for disease to declare itself.
In these conversations, vagal nerve stimulation, EWOT stacked with photobiomodulation, low-dose vascular therapies, creatine, and NAD-support strategies are framed less as isolated hacks and more as ways to stabilize the body’s internal power network—where oxygen delivery, ATP trafficking, and inflammatory set-points shape resilience.
The strategic implication is hard to miss: the next-generation longevity clinic will win by sequencing interventions and measuring biology beyond standard panels—homocysteine, MMP-9, ApoB, Lp(a), inflammatory markers, and functional vascular signals—while treating each patient as an N-of-1 operating system rather than a population average.
This Newsletter Is Sponsored By Casa de Sante.
For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:
Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss
FODMAP Digestive Enzymes – improves absorption and reduces GI side effects
Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome
Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss
Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation
All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.
Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:
HydraLift Collagen Complex – firms and smooths for youthful elasticity
Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress
Needle-Free Wrinkle Smoother – softens fine lines without irritation
Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol
Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles
Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair
Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck
Even Tone Brightening Cream – evens discoloration for radiant, balanced skin
Dr Onyx Adegbola MD PhD
Track Smarter. Eat Better. Thrive. Download the GLP1 Support App at https://casadesante.com/pages/app-glp-1-support-by-dr-onyx-md-phd
Your Longevity Risk May Be in the Room
Another major theme is that high-impact longevity threats may sit in plain sight: The Human Upgrade episode “Your AC Is Making You Dumber” argues that mold, HVAC contamination, dust, humidity, and even vehicle interiors can act as chronic mitochondrial and inflammatory stressors, while “Semen Switch, Chewing Gum, Creatine Cheat, Cancer Plants, and Bedtime Risk” expands the same logic to microplastics and irregular sleep timing.
That reframes prevention in a more strategic way, because it moves the field beyond supplements and lab work into exposure control, circadian discipline, and what might be called infrastructure medicine—the quality of the air, surfaces, rhythms, and sensory inputs people live inside every day.
For busy clinicians and operators, the practical message is powerful: when brain fog, fatigue, endocrine disruption, or cardiometabolic drift seem “mysterious,” the hidden variable may be the environment, and a sharp exposure history or sleep-timing audit may produce more clinical leverage than another routine test panel.
The New Playbook Blends Behavior With Precision Therapy
Across Huberman Lab episodes with Dr. Dacher Keltner, Dr. Nick Epley, Dr. Natalie Crawford, and Dr. Casey Halpern—as well as Peter Attia’s sleep pharmacology discussion—the field keeps making the same point: behaviors that once sounded soft or optional, like awe walks, real social contact, fertility planning, structured grief processing, and circadian repair, are now being presented as direct levers on vagal tone, inflammation, reproductive capacity, neural circuitry, and sleep architecture.
At the same time, The Human Upgrade episodes on Jason Fung’s obesity framework, women’s hormone care, urolithin A, immune-aging markers, and GLP-1-aligned metabolic strategy show a parallel trend toward targeted escalation: pair real-food structure, protein, fasting windows, hormone optimization, mitochondrial support, and selective pharmacology instead of forcing a false choice between lifestyle medicine and therapeutics.
That is the emerging operating model for longevity: not biohacking versus medicine, but a hybrid system that starts with high-return daily behaviors, adds biomarker-guided therapeutics when the signal is strong, and uses the least invasive intervention capable of moving a meaningful endpoint.
This weeks episodes:
1. The Human Upgrade: Biohacking for Longevity & Performance
Why Are Hackers Microdosing “Sex Drugs” Now? : 1425
Published: 2026-03-03
URL: Listen Here
Summary
This episode advocates for precision medicine that integrates multi-omic data, autonomic modulation, and targeted therapeutics to optimize longevity. It highlights vagal nerve stimulation’s ability to downregulate the NLRP3 inflammasome, the need to individualize drugs and peptides, and the centrality of vascular tone/perfusion and mitochondrial function to healthy aging. Some claims are anecdotal and product-related; specific study details were not always provided in the discussion.
Key Takeaways
Precision medicine should move beyond one-size-fits-all epidemiology to N-of-1 care using multi-omics (genomics → transcriptomics → proteomics → metabolomics/exposome) to match the right intervention to the right person at the right time.
Vagal nerve stimulation engages the cholinergic anti-inflammatory pathway (α7nAChR/JAK–STAT/NF-κB) and can downregulate the NLRP3 inflammasome, a central driver of systemic inflammation and fibrosis; simple adjuncts like EGCG may also modulate NLRP3 activity.
Longevity pharmacology must be individualized: metformin is not universally beneficial (mitochondrial blunting/VO2 max concerns), rapamycin safety data are emerging (PEARL trial) but endpoints matter, and low-dose, pathway-targeted use of drugs and peptides (e.g., BPC-157, KPV, CJC-1295 with ipamorelin, PT-141) can have bioregulatory effects when used judiciously.
Vascular tone and perfusion are foundational to brain and sexual health; strategies include nitric oxide support, selective PDE5 inhibitor use (e.g., low-dose tadalafil in appropriate patients), and device-based approaches like acoustic shockwave therapy, which may promote neovascularization and lower MMP-9.
Actionable biomarkers beyond routine labs that inform aging biology include homocysteine, ApoB, Lp(a), TGF-β1, MMP-9, and C4a; pairing these with mitochondrial/energy-oriented interventions (IHHT, photobiomodulation, PEMF, HBOT) and exposome assessment can improve outcomes while AI can help sequence interventions efficiently.
Clinical Insight
Targeting autonomic balance and inflammatory set-points—specifically via vagal nerve stimulation to suppress NLRP3—combined with multi-omic profiling provides a practical, high-leverage way to personalize longevity care beyond traditional risk-factor management.
Actionable Takeaway
In patients with chronic inflammation or dysautonomia, add MMP-9 and homocysteine (along with ApoB, Lp(a), TGF-β1, and C4a when feasible) to baseline labs; if elevated, trial a noninvasive vagal nerve stimulation protocol to engage the cholinergic anti-inflammatory pathway and reassess biomarkers after 6–8 weeks.
2. The Human Upgrade: Biohacking for Longevity & Performance
Why Are Hackers Microdosing “Sex Drugs” Now? : 1425
Published: 2026-03-03
URL: Listen Here
Summary
This episode explores how precision medicine leverages multi-omics, exposome assessment, and autonomic modulation to individualize care, with practical discussion of peptides, low-dose pharmaceuticals (e.g., tadalafil), and advanced biomarkers beyond standard panels. The conversation emphasizes sequencing interventions for mitochondrial and vascular health, measuring transcriptomic responses to confirm epigenetic effects, and safeguarding data as personalized platforms mature.
Key Takeaways
Precision medicine requires an N-of-1, multi-omic approach (genomics, transcriptomics, proteomics, epigenetics, metabolomics, exposomics) to match the right intervention to the right person at the right time.
Autonomic modulation, particularly vagal nerve stimulation, can downregulate inflammatory pathways (e.g., NLRP3 inflammasome via the cholinergic anti-inflammatory pathway) and may improve longevity-relevant markers; EGCG was cited as a practical adjunct.
Microdosing or low-dose use of select pharmaceuticals (e.g., tadalafil for vascular tone) and emerging peptide therapeutics (e.g., BPC-157, KPV, CJC-1295 with ipamorelin/semorelin, PT-141) can be useful for targeted outcomes but should be sequenced thoughtfully; metformin and rapamycin are not universal longevity solutions.
Beyond routine labs, clinicians should consider biomarkers that reflect inflammation and vascular health such as homocysteine, MMP-9, TGF-β1, C4a, nitric oxide-related function, and even cell membrane lipidomics; low cerebral perfusion is common and clinically meaningful.
Biohacking technologies (e.g., intermittent hypoxic–hyperoxic training, photobiomodulation, PEMF, HBOT, acoustic shockwave) can be potent when applied in the right order and tracked with objective data; data privacy and ownership matter as multi-omic and exposome assessments scale.
Clinical Insight
Shifting from population averages to multi-omic, N-of-1 care—while actively modulating the autonomic nervous system—allows physicians to directly influence and verify changes in key inflammatory and vascular pathways (e.g., NLRP3, nitric oxide biology), improving precision and efficiency of interventions.
Actionable Takeaway
For patients with chronic inflammation, dysautonomia, or low perfusion, implement daily noninvasive vagal nerve stimulation (or paced-breathing/HRV training) for 10–20 minutes and track CRP/IL-6 and symptom changes; consider adding a well-tolerated green tea extract providing 200–400 mg EGCG/day as an NLRP3-modulating adjunct, checking for drug–supplement interactions.
3. The Human Upgrade: Biohacking for Longevity & Performance
Your AC Is Making You Dumber : 1444
Published: 2026-04-03
URL: Listen Here
Summary
This episode argues that air-conditioning and water‑damaged indoor environments expose occupants to mycotoxins that impair mitochondrial function, cognition, hormones, metabolism, and sleep, with variable susceptibility driven partly by HLA‑DR genetics. The hosts outline a cost‑conscious, stepwise approach to ‘detoxing’ homes and vehicles—fix moisture/HVAC, oxidize/degrade mycotoxins and VOCs, reseed with environmental probiotics, and protect high‑risk surfaces—alongside humidity and dust control. Limitations: many claims are experiential or product‑specific and not independently detailed in the episode; clinicians should interpret promotional elements cautiously and corroborate with evidence-based resources.
Key Takeaways
Toxic mold and their mycotoxins (e.g., ochratoxin A, zearalenone) are fat‑soluble mitochondrial poisons that can drive multisystem illness—neurocognitive deficits, sleep disturbance with vivid nightmares, mood/behavior changes, endocrine disruption (thyroid, estrogen dominance), weight gain, easy bruising, recurrent infections, and chemical sensitivity.
Susceptibility varies widely; genetics (e.g., HLA‑DR4 variants) and exposure history modulate risk, so one family member may be severely affected while others appear well. Brain SPECT data (Amen Clinics) suggest mold exposure can reduce prefrontal activity and cognition but may be reversible after remediation.
Built environments—especially HVAC systems, ductwork, dust, moisture-prone areas, and vehicles—are common and underrecognized exposure sources; ingestion via mold‑prone foods (coffee, grains, peanuts) also contributes.
Effective management pairs medical care with environmental strategies: identify and fix moisture sources, control indoor humidity (~40–50%), address HVAC and duct contamination, reduce dust, and consider staged decontamination (oxidizing fog/gas to degrade mycotoxins and VOCs, reseeding with environmental probiotics, and protective coatings on high‑risk surfaces).
Porous belongings can carry residual mycotoxins between homes; moving without decontaminating contents often perpetuates illness. Vehicles (cars/RVs) can be significant sources due to mold and VOCs; targeted ‘detox’ is different from standard detailing.
Clinical Insight
In patients with persistent, unexplained multisystem symptoms (fatigue/brain fog, sleep disruption, mood/behavior changes, weight dysregulation, chemical sensitivity), assessing and treating the home/vehicle environment—especially moisture control and HVAC/dust contamination—can be decisive for recovery from mycotoxin-related illness.
Actionable Takeaway
Screen for water‑damaged building exposure in symptomatic patients and recommend a basic home assessment: measure/maintain indoor humidity at 40–50%, use HEPA air filtration and HEPA vacuuming to reduce dust, inspect/clean HVAC and ducts, and initiate validated environmental testing (e.g., dust-based mycotoxin or ERMI/HERTSMI‑2) before escalating medications.
4. The Human Upgrade: Biohacking for Longevity & Performance
Your AC Is Making You Dumber : 1444
Published: 2026-04-03
URL: Listen Here
Summary
Dave Asprey and the SuperStratum team discuss how indoor mold and residual mycotoxins can impair mitochondrial function and contribute to wide-ranging symptoms, with variable patient susceptibility. They outline practical, staged approaches for homes and vehicles—addressing moisture control, HVAC/duct hygiene, dust removal, and targeted decontamination of mycotoxins/VOCs—to complement or follow traditional remediation.
Key Takeaways
The episode centers on indoor mold and mycotoxins as underrecognized drivers of diverse symptoms (fatigue, brain fog, sleep disturbance, mood changes, endocrine disruption, weight gain) via mitochondrial dysfunction and immune dysregulation.
Susceptibility varies widely; about 28% of people may carry HLA-DR4 variants associated with heightened inflammatory responses and reduced ability to clear fat-soluble mycotoxins, which helps explain why household members can be affected differently.
Common exposure sources include water-damaged buildings, high indoor humidity, HVAC/ductwork, dust accumulation, and vehicles; ochratoxin A (OTA) and zearalenone are highlighted as clinically relevant mycotoxins with thyroid and estrogenic effects, respectively.
Post-remediation illness can persist due to residual mycotoxins and VOCs on surfaces and in contents; the discussion emphasizes whole-home strategies: fix moisture sources, maintain 40–50% indoor RH, clean/coat HVAC and ducts, HEPA vacuum dust, and consider targeted decontamination approaches.
The guests discuss a staged approach they use (fogging/‘bombing’ to oxidize mycotoxins/VOCs, followed by environmental probiotics and durable anti-microbial coatings) as a lower-cost adjunct to traditional remediation, and note cars can require similar detox protocols.
Clinical Insight
In patients with otherwise unexplained neurocognitive, endocrine, sleep, or cardiometabolic complaints—especially with a history of dampness or water damage—environmental mycotoxin exposure is a plausible, often overlooked contributor; assessing susceptibility, the built environment (not just visible mold), and residual mycotoxins after remediation can materially influence outcomes.
Actionable Takeaway
Incorporate a brief environmental history and screening into visits for chronic, multisystem complaints: ask about water damage/musty odors, humidity levels, HVAC maintenance, visible condensation, dust burden, and car exposures; advise maintaining indoor RH ~40–50%, fixing moisture intrusions, HEPA vacuuming dust, servicing/cleaning HVAC and ducts, and consider referral to qualified mold assessment/remediation when indicated.
5. Huberman Lab
Cultivating Awe & Emotional Connection in Daily Life | Dr. Dacher Keltner
Published: 2026-04-06
URL: Listen Here
Summary
This episode details the science of awe—how shifting from narrow to vast perception, engaging with nature and music, and synchronizing in groups reliably evokes awe with tangible benefits across inflammation, vagal tone, pain, and well-being. Practical protocols (e.g., awe walks) offer clinicians scalable tools to augment care, while insights on social bonding (embarrassment/teasing) and carefully supervised psychedelic-assisted therapy highlight additional pathways to strengthen connection and resilience. Note: Some findings (e.g., long COVID improvements from brief daily awe) are preliminary and require further peer-reviewed validation.
Key Takeaways
Awe is a measurable, health-relevant state linked to increased vagal tone (HRV), reduced inflammation, lower physical pain, and reported improvement in long COVID symptoms from brief daily awe practices.
Shifting perceptual “aperture” from small to vast (for example, moving from focusing on a leaf to the canopy to the sky/horizon) reliably evokes awe and can recalibrate arousal, time perception, and self-focus toward equanimity.
An 8-week, once-weekly 20–30 minute “awe walk” intervention in older adults increased awe, kindness, and vast attention in daily life and reduced bodily pain, with longer-term follow-up suggesting brain health benefits.
Group synchrony (music, sport, dance, chanting, shared rituals) rapidly fosters bonding and collective identity, consistent with the concept of collective effervescence; embarrassment and prosocial teasing within groups signal commitment to norms and strengthen cohesion.
Psychedelics (classic serotonergic agents) can induce profound awe and may aid treatment-resistant conditions (e.g., end-of-life anxiety, depression, PTSD) when used in structured, safe, culturally respectful settings; microdosing lacks strong clinical evidence.
Clinical Insight
Awe can be deliberately elicited (nature, music, horizons, group synchrony) and functions as a low-cost, low-risk adjunct that measurably improves autonomic balance (vagal tone), reduces inflammatory load and pain, and supports mental health—making it a viable element to integrate into preventive care and rehabilitation plans.
Actionable Takeaway
Prescribe a weekly 20–30 minute awe walk for 8 weeks: ask patients to slow their pace and breath (prolonged exhalations), and to move attention from small to vast (e.g., a leaf → tree → treeline → clouds/horizon). Encourage one brief daily “micro-awe” (≈60 seconds via nature, music, or vistas). Track simple outcomes (pain ratings, mood/sleep, HRV if available) and consider adding music- or nature-based sessions for reinforcement.
6. Huberman Lab
Essentials: The Biology of Aggression, Mating & Arousal | Dr. David Anderson
Published: 2026-04-09
URL: Listen Here
Summary
This episode reviews the neurobiology of internal states governing aggression, mating, and arousal, emphasizing hypothalamic circuit logic, hormone signaling (notably estrogen pathways), and brain–body interactions. It highlights how social isolation engages conserved tachykinin mechanisms that amplify aggression and anxiety, suggesting concrete translational avenues (e.g., NK3 antagonists) while underscoring the clinical need to assess and address isolation.
Key Takeaways
Emotions are best understood as internal brain states (like arousal or motivation) that reshape input–output transformations of neural circuits; unlike reflexes, they often persist beyond the trigger and generalize across contexts.
Aggression is a heterogeneous set of behaviors supported by distinct but adjacent hypothalamic circuits (VMHvl): fear-related neurons can hierarchically suppress offensive aggression, and VMH integrates multisensory inputs while broadcasting low-dimensional ‘attack pressure’ signals widely.
Sex hormones do not map simply onto behavior: estrogen receptor–expressing neurons in male VMH are necessary for aggression, many testosterone effects are mediated via aromatization to estrogen, and in females, discrete VMH ER+ neuron subsets differentially control mating versus fighting.
Mating and aggression circuits exhibit reciprocal control: activating medial preoptic area (MPOA) ‘mating’ neurons can abruptly switch a male from fighting to courtship, whereas VMHvl ‘aggression’ neurons bias toward attack; PAG acts as a downstream ‘switchboard’ coordinating pain modulation and innate action patterns.
Social isolation robustly upregulates tachykinin signaling (e.g., tachykinin 2) across species, increasing aggression, fear, and anxiety; in mice, an NK3 receptor antagonist (osanotont) reverses isolation-induced phenotypes without sedation, highlighting a translational target for isolation-related psychopathology.
Clinical Insight
Social isolation is a potent, biologically mediated driver of negative affect and aggression—partly via tachykinin 2 signaling—with preclinical evidence that NK3 receptor antagonism can normalize isolation-induced aggression, fear, and anxiety without sedation; clinicians should treat isolation as a modifiable risk factor rather than a benign social state.
Actionable Takeaway
Routinely screen patients for social isolation (e.g., recent bereavement, living alone, limited social contact) and implement mitigation strategies—structured social engagement, therapy referrals, family/caregiver involvement, and follow-up touchpoints—especially in individuals showing increased irritability, anxiety, or aggression.
7. Huberman Lab
Essentials: The Biology of Aggression, Mating & Arousal | Dr. David Anderson
Published: 2026-04-09
URL: Listen Here
Summary
This episode synthesizes neural circuit, hormonal, and neuropeptide mechanisms underlying aggression, mating, arousal, and pain modulation. Key themes include hypothalamic control of offensive aggression and its suppression by fear, estrogenic regulation of male aggression, sex-specific VMH circuits for mating vs fighting, and tachykinin-driven effects of social isolation that are reversible with NK3R antagonism—findings with clear translational relevance for stress-related behavioral health.
Key Takeaways
Emotions are best understood as internal brain states (like arousal, motivation, sleep) that transform how inputs map to outputs; compared to reflexes, emotion states show persistence and generalization beyond the initial trigger.
Aggression is a behavior that can arise from different internal states (e.g., anger, fear, hunger); in mice, ventromedial hypothalamus (VMHvl) circuits drive offensive, positively valenced aggression, while adjacent hypothalamic fear circuits can hierarchically suppress fighting.
Hormonal control of aggression in males depends critically on estrogen receptor–expressing VMH neurons and aromatization of testosterone to estrogen; estrogen implants can restore aggression in castrated male mice.
Sex-specific neural architecture shapes behavior: in females, distinct estrogen receptor–positive VMH subsets separately control mating and fighting, and medial preoptic area (MPOA) ‘mating’ neurons can acutely suppress ongoing aggression (antagonistic VMH–MPOA interactions).
Social isolation upregulates tachykinin signaling (Tac2/neurokinin B) across the brain to increase aggression, fear, and anxiety; an NK3 receptor antagonist (osanetant) reverses these effects in mice. The periaqueductal gray (PAG) acts as a hub for innate behaviors and supports endogenous, state-dependent analgesia (e.g., during fear/defense).
Clinical Insight
Chronic social isolation induces a Tac2/NK3R-mediated, druggable brain state that heightens aggression, fear, and anxiety—highlighting both the clinical importance of assessing isolation/bereavement and the translational potential of NK3 receptor antagonism for stress-related behavioral dysregulation.
Actionable Takeaway
Routinely screen patients experiencing prolonged social isolation or bereavement for irritability, aggression, and anxiety, and implement structured social reconnection strategies (e.g., group therapy, regular follow-ups, community engagement) to mitigate these biologically primed risk states.
8. The Human Upgrade: Biohacking for Longevity & Performance
Why Doctors Can’t Fix Women in 2026 : 1446
Published: 2026-04-09
URL: Listen Here
Summary
This episode argues that modern care under-treats women’s hormones and that personalized, bioidentical HRT—especially estradiol and progesterone delivered vaginally at systemic doses—can be a cornerstone for restoring libido, cognition, mood, sleep, gut/gallbladder function, and overall vitality. The guests emphasize treating to clinical response (not just numbers), considering genetics and neurotransmitters, and leveraging nutrition (adequate protein, cautious fiber, iodine) while using testosterone judiciously. Note: Many claims were experiential and not directly cited; sponsor content and controversial viewpoints are included.
Key Takeaways
Personalized, bioidentical hormone replacement (estradiol, progesterone, ± testosterone) is presented as foundational for many symptomatic women—even premenopausally—with dosing guided by symptoms and function rather than fixed lab ‘norms’ or low-dose patches/pills.
Systemic vaginal delivery of estradiol and progesterone is advocated as higher bioavailability than oral/topical/patch routes, aiming to suppress elevated FSH and improve cognition, sleep, mood, gut/gallbladder function, and sexual function; oral progesterone’s sedating effects may arise from liver-derived metabolites.
Testosterone can benefit women’s libido and cognition but excess transdermal/injected T may increase DHT/aromatization or disrupt the vaginal microbiome; many women may normalize T by optimizing progesterone, with optional low-dose topical T for event-based arousal.
Diet and environment meaningfully influence hormones and neurotransmitters: prioritize adequate protein (supporting dopamine/COMT), avoid excessive insoluble fiber and certain phytoestrogens, consider iodine repletion for breast/uterine health, and be mindful of high-oxalate foods (e.g., matcha/spinach) implicated in kidney stones and tissue symptoms.
Evaluate and treat holistically: use FSH and symptom clusters to detect early dysfunction, recognize genetic/epigenetic differences (e.g., COMT) in hormone clearance, consider neurotransmitter support (dopamine/norepinephrine/serotonin), and avoid focusing on thyroid alone when sex-hormone deficits drive multi-system complaints.
Clinical Insight
For women with multi-system symptoms (mood, sleep, gut, libido, cognitive), adequately dosed, bioidentical estradiol plus progesterone—preferably via systemic vaginal delivery—and personalized titration to clinical response can restore function across brain, immune, gut, and sexual domains; labs (including FSH) inform but should not replace symptom-guided care.
Actionable Takeaway
In an appropriate symptomatic woman (even <45), obtain FSH, estradiol, progesterone, total/free testosterone, SHBG, DHEA-S, and thyroid panel; if findings and history suggest ovarian under-function, initiate a trial of bioidentical estradiol + progesterone via systemic vaginal delivery and titrate every 6–8 weeks to symptom relief while reinforcing adequate protein intake and avoiding excessive insoluble fiber.
9. The Human Upgrade: Biohacking for Longevity & Performance
Superhuman Contact Lenses, Motivation Supplement Stack, Cat Scratches Cause Brain Fog, Amino Acid Shortening Lifespan, and more... : 1448
Published: 2026-04-10
URL: Listen Here
Summary
This episode highlights overlooked inputs—stealth infections, amino acid balance, sensory light processing, micronutrient status, and olfactory cues—that materially affect cognition, motivation, and autonomic tone. It offers practical steps clinicians can use now: targeted PCR testing for Bartonella, judicious lab monitoring around tyrosine, nutrient stacking to bolster motivation, and low-cost sensory strategies to reduce cognitive and stress load.
Key Takeaways
Cat scratches/bites can transmit Bartonella, a stealth infection linked to chronic brain fog, mood instability, and fatigue; standard serology often misses it—PCR testing is preferred and may require referral to a Lyme-literate clinician.
A Mendelian randomization analysis (~270,000 participants) associates higher circulating tyrosine with nearly one year shorter lifespan in men (not women), potentially via myeloperoxidase-driven formation of inflammatory meta-tyrosine; consider measuring plasma tyrosine and phenylalanine and avoiding unnecessary tyrosine supplementation, especially in men.
Tinted contact lenses (Altius) reportedly reduce chromatic aberration by 53% and improve contrast by 20–30%, potentially lowering visual processing load and enhancing performance; spectrum-filtering eyewear (e.g., TrueDark) and screen apps (Flux/Iris) are adjuncts.
A randomized, placebo-controlled crossover trial from the University of the Philippines found a 4-week stack (taurine 2 g, methylfolate 800 mcg, P5P 50 mg, methylcobalamin 1 mg) increased effort-based motivation and reduced attention lapses, plausibly via astrocytic glutathione support of prefrontal function.
A Monell Chemical Senses Center analysis indicates a 30-second deep nasal inhalation of floral scents can lower heart rate by 5–10 bpm and shift autonomic tone toward parasympathetic; lavender has the strongest RCT support, but pleasant florals broadly appear effective.
Clinical Insight
In patients with persistent neurocognitive or mood symptoms and a history of cat scratches/bites, Bartonella infection is likely underrecognized; order a Bartonella PCR (not just serology) and consider referral to a tick-borne disease–literate clinician, as antibody tests can miss intracellular, tissue-resident infections.
Actionable Takeaway
For patients (especially men) using tyrosine-containing supplements or very high-protein diets, obtain a fasting plasma tyrosine and phenylalanine panel (Quest/LabCorp) and review inflammatory markers; avoid or reduce tyrosine supplementation if levels are high or the tyrosine:phenylalanine ratio approaches/exceeds 10:1.
10. The Human Upgrade: Biohacking for Longevity & Performance
CDC Director Jim O’Neill on Fixing America’s Broken Food Policy : 1449
Published: 2026-04-14
URL: Listen Here
Summary
This episode features Jim O’Neill outlining an HHS/CDC push to overhaul U.S. food guidance and aging research while refocusing CDC on infectious diseases. Highlights include whole‑food, higher‑protein dietary guidance with forthcoming RCTs on saturated fat, large ARPA‑H investments in causal aging biomarkers and organ bioprinting, and greater openness to AI, wearables, non‑pharma therapies, and GLP‑1s. Several claims are policy announcements or opinions presented without primary citations.
Key Takeaways
The guest describes newly released federal dietary guidelines that emphasize whole and minimally processed foods, higher protein intake (1.2–1.6 g/kg/day), and allow meat and full‑fat dairy, while de-emphasizing refined grains and ultra‑processed foods; randomized controlled trials on saturated fats are being initiated.
HHS is prioritizing rigorous replication and aging science, including a reported $144M ARPA‑H initiative to identify causal biomarkers of aging and an organ bioprinting program that has printed a pediatric heart/vasculature (not yet implanted).
CDC is being refocused on infectious diseases, with examples cited of assisting to contain Ebola (DRC) and Marburg (Ethiopia), alongside a stated goal of rebuilding public trust through transparency.
There is openness to evaluating non‑pharmaceutical interventions (e.g., ozone therapy) with the same standards as drugs, and to integrating AI and wearables into care and surveillance—paired with strong patient consent and privacy protections.
Clinical and policy notes include support for GLP‑1s in obesity treatment, an ongoing review of upper vitamin D limits, and improvements to school meals aligned with the updated guidelines.
Clinical Insight
A shift toward whole‑food, higher‑protein nutrition with a more individualized view of dietary fats suggests clinicians should reassess grain‑centric, low‑fat counseling and focus on reducing ultra‑processed carbohydrates while tailoring fat and protein recommendations to each patient’s metabolic risk and goals.
Actionable Takeaway
For adult patients—especially those with metabolic syndrome risk or sarcopenia—calculate and document an individualized daily protein target of 1.2–1.6 g/kg from whole‑food sources, pair this with counseling to minimize ultra‑processed/refined carbohydrates, and reassess lipid/metabolic labs to tailor fat recommendations.
11. Huberman Lab
How Women Can Improve Their Fertility & Hormone Health | Dr. Natalie Crawford
Published: 2026-04-13
URL: Listen Here
Summary
Dr. Crawford details a proactive, science‑based roadmap for improving female fertility and hormone health: use AMH and ovulation tracking to detect issues early, leverage high‑impact lifestyle changes and targeted supplements during the “trimester zero,” and apply appropriate medical tools without waiting for failure. She emphasizes avoiding cannabis and nicotine, practical contraception off‑ramp timing, and clarifies that egg freezing/IVF do not reduce ovarian reserve, while highlighting select promising but still investigational therapies. Note: Summary reflects the provided transcript and may omit topics discussed outside these excerpts.
Key Takeaways
Proactive fertility assessment matters: Anti-Müllerian Hormone (AMH) testing estimates ovarian reserve (not egg quality) and can guide life and treatment planning; it’s inexpensive (~$79) and useful even before trying to conceive.
Track ovulation, not just periods: A luteal phase <11 days is an early red flag for ovulatory dysfunction; avoid NSAIDs except during menses because they can block follicle rupture and ovulation.
Lifestyle and exposures strongly influence fertility and hormone health: Prioritize sleep (7–9 h), stress control, muscle building, anti-inflammatory nutrition, and toxin minimization; avoid cannabis and nicotine (both sexes), which impair gametes and increase miscarriage risk.
Evidence-supported preconception supplements: Begin a prenatal (with folate), CoQ10, omega-3 fatty acids, and vitamin D; for male partners, add L‑carnitine (± zinc/selenium). Consider low-dose melatonin (1–3 mg) for sleep/inflammation preconception, then stop in pregnancy.
Clinical nuances: Egg freezing/IVF do not deplete ovarian reserve; stop combined OCPs 3–6 months before trying to learn ovulation, remove levonorgestrel IUD ~6 months before attempting conception, and avoid Depo‑Provera if planning pregnancy within 1–2 years. Selective, emerging tools (e.g., GLP‑1s in insulin resistance/inflammation, intrauterine PRP for implantation failure) show promise; ovarian PRP and red light remain investigational.
Clinical Insight
Replace the “fail‑first” model with an early, data‑driven approach: normalize AMH screening and ovulation/luteal‑phase tracking for reproductive‑age women to surface problems sooner and tailor timely lifestyle, medical, or procedural interventions that can materially improve outcomes.
Actionable Takeaway
At routine visits for women who might want children, offer AMH testing and brief ovulation‑tracking education, and initiate a 60–90‑day preconception plan: sleep 7–9 h; avoid cannabis/nicotine and NSAIDs outside menses; start prenatal (folate), CoQ10 (200–400 mg/day), omega‑3 (1–2 g/day EPA+DHA), vitamin D per level; counsel partners to add L‑carnitine (≈2 g/day); reassess promptly if luteal phase <11 days, cycles irregular, age ≥35, or ≥2 pregnancy losses.
12. The Human Upgrade: Biohacking for Longevity & Performance
CDC Director Jim O’Neill on Fixing America’s Broken Food Policy : 1449
Published: 2026-04-14
URL: Listen Here
Summary
Acting CDC Director Jim O’Neill outlines a pivot in U.S. food policy toward whole foods and away from ultra‑processed, grain‑heavy patterns, alongside active trials reassessing saturated fats. He details federal investments in causal aging biomarkers via ARPA‑H, broader acceptance of AI and wearables (with consent) in care, a renewed CDC focus on infectious diseases, support for GLP‑1s in obesity management, and a review of vitamin D limits. Several points reflect evolving policy announcements described in the interview.
Key Takeaways
HHS/CDC leadership reports newly announced U.S. dietary guidelines that emphasize whole, minimally processed foods, reduce reliance on grains and ultra-processed foods, and affirm that meat and full‑fat dairy can fit into a healthy diet; randomized controlled trials on saturated fats are underway.
The government is prioritizing replication and rigor, including a $144M ARPA-H initiative to develop and FDA‑validate causal biomarkers of aging to enable surrogate endpoints for prevention and longevity therapies.
CDC is refocusing on infectious disease and highlights recent collaborations that contained Ebola (DRC) and Marburg (Ethiopia), while rebuilding public trust via transparency and focus.
There is openness to testing non‑pharmaceutical and biohacking innovations (e.g., ozone therapy) with the same scientific standards, and expanded use of wearables and AI for early detection and clinical decision support, with strong emphasis on privacy and informed consent.
GLP‑1 receptor agonists are supported as effective tools for obesity when paired with nutrition and fitness, vitamin D upper‑limit recommendations are under review, and school meals are viewed as a high‑leverage point for improving national nutrition.
Clinical Insight
Expect a policy shift in federal nutrition guidance—toward whole, minimally processed foods with adequate protein and without blanket avoidance of saturated fat/full‑fat dairy—which, combined with GLP‑1 use where appropriate, can reshape counseling and management of obesity and cardiometabolic disease.
Actionable Takeaway
Update nutrition counseling now: guide patients to prioritize whole foods and minimize ultra‑processed/refined grains, target 1.2–1.6 g/kg/day protein, individualize recommendations on saturated fat based on cardiometabolic risk, and routinely measure 25‑OH vitamin D with supplementation as needed under monitoring.
13. The Human Upgrade: Biohacking for Longevity & Performance
1 Cup Every Morning Helped Me Lose 100 Pounds (Drink THIS) : 1452
Published: 2026-04-19
URL: Listen Here
Summary
This episode is a first‑person narrative promoting butter/MCT coffee, intermittent fasting, and a high‑fat, low‑grain approach while labeling common nutrition beliefs as myths and de‑emphasizing exercise for fat loss. It reflects popular biohacking perspectives but provides limited primary evidence; clinicians may encounter patients adopting these strategies and should contextualize them within current guidelines and individualized risk assessment.
Key Takeaways
Host Dave Asprey attributes losing over 100 pounds to starting mornings with “butter coffee” (grass‑fed butter + MCT oil) and practicing intermittent fasting, emphasizing satiety, steady energy, and reduced cravings.
He presents nine “myths” he believes hinder weight loss: saturated fat is harmful; low‑fat diets are healthy; calories‑in/calories‑out drives weight change; frequent small meals boost metabolism; all vegetables are beneficial (citing anti‑nutrients in some); whole grains are healthy; fruit is universally healthy (warns about fructose); breakfast is essential; and exercise is the primary tool for fat loss.
Asprey advocates prioritizing saturated fats from grass‑fed animal sources and coconut oil, avoiding trans fats and processed seed/vegetable oils, minimizing grains and high‑fructose fruits, and selecting lower anti‑nutrient vegetables.
He claims mold/mycotoxins in some coffees drive jitters and poorer tolerance, recommending “clean” coffee; he also argues diet quality and fasting outweigh exercise for fat loss and warns that overtraining may elevate cortisol.
The episode is largely anecdotal and promotional, referencing his books and commercial products; specific primary research citations supporting many claims are not provided.
Clinical Insight
Patients may inquire about high‑fat morning beverages and time‑restricted eating to curb hunger and aid weight management; clinicians should individualize guidance and, if trialed, monitor cardiometabolic risk (e.g., LDL‑C/apoB, glycemia, liver enzymes) given that several assertions—especially high saturated fat intake and broad avoidance of plant foods/grains—diverge from prevailing evidence‑based guidelines.
Actionable Takeaway
When patients ask about “butter coffee” or intermittent fasting, offer a short, supervised 2–4 week trial of time‑restricted eating (e.g., 14–16 hour daily fast) focused on minimally processed foods; advise non‑caloric morning beverages in higher‑risk patients, track hunger/weight/glucose, and recheck lipids as indicated before making longer‑term changes.
14. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
Jason Fung contends that contemporary obesity is driven primarily by hedonic and conditioned hunger magnified by ultra-processed foods and pervasive eating cues, not by a simple excess of calories. He outlines three rules—ditch ultra-processed foods, reintroduce fasting windows, and engineer environments—to lower hunger and make weight loss sustainable, positioning GLP‑1 medications as appetite-lowering tools to use alongside real‑food and behavior change.
Key Takeaways
Hunger has three distinct drivers—homeostatic (physical), hedonic (pleasure), and conditioned (cue-driven/social)—and the latter two dominate modern overeating.
Ultra-processed foods are engineered to maximize reward and minimize satiety (rapid absorption, texture modifiers, emulsifiers, flavor enhancers), amplifying hedonic and conditioned hunger independent of calories.
Sustained weight loss rarely results from calorie restriction alone; approaches that reduce hunger (diet quality, meal timing/fasting, environmental redesign) work better. GLP-1 receptor agonists help mainly by suppressing appetite but require concurrent habit change for durability.
Fung’s three golden rules: eliminate ultra-processed foods; include consistent fasting periods (reduce meal frequency/snacking); and redesign schedules/environments to remove eating cues and food noise.
Behavioral and mindset tools—such as extinction and counter-conditioning, eating only at a table, and reframing ultra-processed items as “not food”—can deprogram conditioned hunger and reduce cravings.
Clinical Insight
For patients with obesity, target hunger biology and conditioned cues rather than caloric math: assess and modify diet quality (real food over ultra-processed), structure meal timing (fasting windows), and reshape social/environmental triggers; consider GLP-1 agents to reduce appetite while concurrently coaching durable nutrition and behavioral skills.
Actionable Takeaway
At the next visit, screen for the three hunger types and initiate a 4‑week protocol: eliminate ultra-processed foods; eat 2–3 real‑food meals within an 8–10‑hour window with no calories between; and remove eating cues (no eating in the car/TV, keep snacks out of sight). If on a GLP‑1, pair with nutrition/behavioral coaching to build lasting habits.
15. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
This episode reframes obesity care around managing hunger biology and learned cues rather than prescribing calorie restriction. Fung explains how ultra-processed foods and ubiquitous food cues amplify hedonic and conditioned hunger, and outlines three practical rules—cut UPFs, add fasting windows, and redesign environments—to align physiology and behavior. GLP-1 medications can help by suppressing hunger, but sustained success depends on concurrent nutrition and behavioral retraining.
Key Takeaways
Overeating is primarily a hunger problem—not a calorie problem—with three contributors: homeostatic (physical), hedonic (pleasure-driven), and conditioned (cue-driven) hunger; in modern environments, conditioned and hedonic hunger dominate.
Ultra-processed foods are engineered to maximize reward (rapid absorption, intense flavors, optimized texture) while minimizing satiety, reinforcing both hedonic and conditioned hunger and driving habitual overconsumption.
Calorie restriction alone fails long term because physiology adapts and hunger intensifies; focusing on reducing hunger signals via food quality, structured fasting, and behavioral strategies is more sustainable.
GLP-1 receptor agonists reduce hunger and can enable weight loss, but durable results require concurrent learning of real-food eating patterns and environment/cue redesign to prevent relapse when medications stop.
Dr. Fung’s three golden rules: (1) eliminate ultra-processed foods; (2) establish consistent fasting windows and stop constant snacking; (3) redesign schedules and environments to reduce food cues, using counterconditioning and extinction to retrain conditioned hunger.
Clinical Insight
For sustained weight loss, clinicians should target the biology and behavior of hunger—especially conditioned and hedonic drivers—by replacing ultra-processed foods with real foods, implementing time-based fasting windows, and modifying environments/cues; pharmacologic appetite suppression (e.g., GLP-1 RAs) can be an adjunct but must be paired with nutrition and behavior change to maintain results.
Actionable Takeaway
Start a two-week intervention: advise patients to remove ultra-processed foods from home/work, eat 2–3 whole-food meals daily with adequate protein and natural fats, avoid between-meal snacks, and keep a 12–14-hour overnight fast; restrict eating to a table (not cars/TV) and replace evening snacking with unsweetened tea to extinguish conditioned cues, then reassess hunger/craving patterns at follow-up.
16. The Human Upgrade: Biohacking for Longevity & Performance
Jason Fung: 3 Rules to Lose 50 Pounds Without Ever Counting a Calorie : 1453
Published: 2026-04-21
URL: Listen Here
Summary
Dr. Jason Fung reframes weight loss around hunger biology and environment, arguing that hedonic and conditioned hunger—amplified by ultra-processed foods and pervasive cues—drive overeating more than true physical hunger. Sustainable management targets appetite regulation (real food, fasting windows, environment design, behavioral techniques) and may incorporate GLP-1 therapy as a tool while patients build lasting dietary and behavioral skills.
Key Takeaways
Obesity is driven by three types of hunger—homeostatic (physical), hedonic (pleasure-driven), and conditioned (social/cue-driven)—with conditioned and hedonic hunger now dominating due to environment, marketing, and constant food cues.
Chronic calorie restriction fails long-term because appetite and hormones (e.g., insulin, GLP-1 pathways) govern intake and expenditure; GLP-1 receptor agonists work by lowering hunger but require concurrent nutrition and behavior change for durable results.
Ultra-processed foods (UPFs) are engineered to maximize reward (rapid absorption, flavor enhancers, emulsifiers/texturizers) and minimize satiety, amplifying ‘food noise,’ cravings, and overeating; additives like carrageenan/xanthan gum can worsen mouthfeel-driven intake and may irritate the gut.
Fung’s three golden rules: (1) eliminate UPFs in favor of real, nutrient-dense foods; (2) ensure an adequate fasting window and stop constant snacking; (3) redesign schedule and environment (eat at a table, avoid eating while driving/TV, manage cues) to reduce conditioned hunger.
Behavioral strategies such as counterconditioning (pairing cravings with aversive imagery) and extinction/substitution (e.g., tea instead of snacks while watching TV), plus a mindset shift to view UPFs as “not food,” help deprogram conditioned eating.
Clinical Insight
Effective obesity care centers on diagnosing and treating hunger dysregulation (hedonic and conditioned drivers) and hormonal responses to food, not prescribing simple calorie restriction; prioritize removal of ultra-processed foods, structured fasting/eating windows, and environmental cue control, using GLP-1s as adjuncts to reduce hunger while patients learn durable eating behaviors.
Actionable Takeaway
Start a 2–4 week ‘real food + fasting’ trial: remove all ultra-processed items and sweetened/‘diet’ beverages; eat 2–3 real-food meals daily emphasizing protein and natural fats; maintain a 12–16 hour overnight fast with no snacking; and restrict eating to a table—then reassess hunger, satiety, and weight at follow-up.
17. The Human Upgrade: Biohacking for Longevity & Performance
Inside Kambo: Poison, Purging, and The People Who Swear By It : 1455
Published: 2026-04-24
URL: Listen Here
Summary
This episode examines Kambo’s traditional origins, modern ceremonial use, administration, peptide-based mechanisms, safety profile, and preliminary human outcomes. It highlights practical risk-reduction (especially electrolyte management), underscores the paucity of rigorous clinical data, and discusses sustainability and training standards relevant to clinicians advising patients exploring Kambo.
Key Takeaways
Kambo (frog skin secretion from Phyllomedusa bicolor) is applied via superficial skin burns and is not a classical psychedelic; it induces a rapid, intense 20–30 minute experience marked by flushing, tachycardia, nausea/vomiting, sweating, shaking, transient facial swelling (“frog face”), and possible bowel movements or syncope.
Traditional Amazonian use centered on ‘hunting magic’ (adaptogenic effects like heightened perception and stamina); modern practice emphasizes ritual, trauma work, and broad wellness aims, with anecdotal utility reported for pain, autoimmune issues, infections, metabolic disease, and addiction.
Pharmacology involves at least 27 peptide analogs across eight families (e.g., opioid-receptor–active and vagal-acting peptides, antimicrobial peptides) producing vascular, GI, autonomic, and possible antipsychotic effects; however, rigorous human research on the full Kambo cocktail is sparse.
Safety hinges on preventing hyponatremia from overhydration (especially when stacked with low-salt ayahuasca dieta/fasting) and supervising to mitigate aspiration and falls; with careful screening, electrolyte management, and close monitoring, serious adverse events appear uncommon.
Emerging data (practice datasets, a post-session survey, and a prospective human study pending publication) suggest improvements in mood, mindfulness, happiness, pain, and fatigue after Kambo; sustainability and standardization remain challenges, spurring conservation work and attempts to characterize/synthesize peptide mixtures.
Clinical Insight
Kambo is a peptide-rich, non-psychedelic intervention with meaningful autonomic, GI, antimicrobial, and opioid-receptor effects that may yield short-term improvements in mood, mindfulness, and pain—yet its safe application in practice depends primarily on rigorous screening and proactive electrolyte management to prevent hyponatremia.
Actionable Takeaway
If a patient plans to undergo Kambo, counsel them to avoid overhydration: use salted fluids or oral electrolyte solution (e.g., add 1/4–1/2 tsp sea salt per liter of water), avoid low-salt/fasting protocols and stacking with ayahuasca within 24–48 hours, and ensure the session is supervised by a trained practitioner who monitors for syncope/aspiration.
18. Huberman Lab
Male Roles, Obligations and Options for Building a Fulfilling Life | Scott Galloway
Published: 2026-04-27
URL: Listen Here
Summary
This episode examines modern male roles and well-being, advancing a positive masculinity framework (provider–protector–procreator plus service) and concrete habits that build purpose, skills, and relationships. It highlights Big Tech’s role in compulsive use and isolation, advocates for mentorship and national service, and outlines policy levers (antitrust, algorithmic liability, age-gating) and personal behaviors clinicians can reinforce to improve mental health and social outcomes.
Key Takeaways
Galloway proposes a constructive masculinity code—provider, protector, procreator—augmented by service and the goal of creating “surplus value” (giving more than one takes).
Practical plan for struggling young men: reclaim screen time; train hard (≥3x/week); work outside the home (~30 hrs/week when feasible); engage weekly in team/service groups; and practice graded social “approaches,” embracing rejection as a skill-builder.
Big Tech and algorithmic feeds foster compulsive phone use, isolation, and polarization; policy remedies discussed include antitrust actions, algorithmic liability (Section 230 reform), and age-gating social media for minors.
Male mentorship and (ideally) national service are framed as high-yield solutions to purpose, skill development, and social cohesion—especially critical for boys lacking an involved male role model.
Societal/economic context matters: wealth transfer from young to old, higher-ed gatekeeping, and limited vocational on-ramps are linked to male underachievement and relationship/fertility headwinds; clinicians should recognize porn overuse as an under-researched, potentially demotivating behavior, while alcohol/THC can be net harmful or helpful depending on context and use patterns.
Clinical Insight
For young and midlife men, social isolation coupled with compulsive digital use (better conceptualized as an OCD-like compulsion loop than simple ‘dopamine hits’) is a potent driver of anxiety, depression, and suicidality; brief clinical screening and counseling that redirect time toward structured exercise, out-of-home work/school, service/mentorship, and graded real-world social engagement can meaningfully improve mental health and functioning.
Actionable Takeaway
In visits with adolescent and young adult males, add a 4-point screen—1) daily screen time and app limits, 2) exercise ≥3 days/week (resistance and/or endurance), 3) hours spent working or studying outside the home, 4) weekly group/service participation—then prescribe a 2–4 week trial to reallocate at least 8 hours/week from phone use to those activities and provide a mentorship or Big Brothers Big Sisters referral if a stable male role model is lacking.
19. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode outlines how EWOT and red/near-infrared light therapy can be mechanistically complementary: exercise-driven hyperoxia improves oxygen delivery while PBM increases mitochondrial oxygen demand and nitric oxide–mediated microvascular perfusion. The approach targets endothelial and mitochondrial dysfunction implicated in fatigue, chronic inflammation, and recovery limitations, with a practical protocol of 15 minutes of EWOT followed by immediate PBM. Few specific clinical trials were cited during the conversation; recommendations were largely mechanistic and experiential.
Key Takeaways
Exercise with Oxygen Therapy (EWOT) delivers ~93% oxygen during 10–15 minutes of light-to-moderate exercise using a concentrator and large reservoir bag, leveraging exercise-induced increases in ventilation, heart rate, vasodilation, and pressure gradients to drive oxygen deeper into tissues than resting oxygen supplementation.
Chronic inflammation and endothelial dysfunction impair microcirculation (pseudo-hypoxia) even when pulse oximetry is normal; swollen endothelial cells and less-flexible RBCs limit capillary oxygen delivery, pushing cells toward anaerobic metabolism, ROS production, and a self-reinforcing inflammatory loop.
Red/near-infrared photobiomodulation (PBM) enhances mitochondrial function by increasing oxygen demand and releasing nitric oxide for vasodilation; stacking PBM immediately after EWOT (when circulation and tissue oxygen levels are elevated) amplifies outcomes (energy, sleep, pain, recovery).
A practical stack advocated: ~15 minutes of EWOT followed immediately by 10–20 minutes of red/NIR light (multiple red and NIR wavelengths) targeted to symptomatic areas or whole body to pair oxygen supply with mitochondrial uptake.
Potential use cases discussed include fatigue, long-COVID/lung injury, endothelial and microvascular dysfunction, ‘anaerobic’ infections (e.g., Lyme), and detox support; the episode’s claims were primarily mechanistic and experiential, with few specific trials cited.
Clinical Insight
Tissue-level hypoxia from microvascular/endothelial dysfunction can persist despite normal SpO2; combining EWOT to enhance oxygen delivery with photobiomodulation to increase mitochondrial oxygen utilization and nitric oxide–mediated perfusion may help break cycles of low energy, inflammation, and impaired recovery.
Actionable Takeaway
For appropriate patients, trial a stacked protocol: 10–15 minutes of moderate EWOT (reservoir-fed ~93% FiO2) followed immediately by 10–15 minutes of red/NIR photobiomodulation (e.g., 620–660 nm and 800–1050 nm) targeted to key regions (e.g., lungs, neck/shoulders, lower limbs), while monitoring HR/BP/SpO2 and tracking functional markers (symptoms, 6MWT/VO2 proxy, and if available pulse wave velocity). Screen for contraindications to high FiO2 and follow oxygen safety protocols.
20. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode explores how EWOT and red/near-infrared light target complementary sides of cellular energetics: EWOT boosts oxygen delivery during exercise, while photobiomodulation increases mitochondrial oxygen use and nitric oxide signaling. By addressing endothelial/microcirculatory dysfunction and mitochondrial inefficiency—common in aging and chronic disease—the combined approach may enhance energy, recovery, and vascular health, with practical protocols feasible at home.
Key Takeaways
Exercise with Oxygen Therapy (EWOT) uses a concentrator and large reservoir to deliver ~93% oxygen during 15 minutes of moderate exercise, leveraging exercise-induced vasodilation and pressure gradients to drive oxygen deeper into hypoxic tissues.
Aging and chronic illness often feature microcirculatory dysfunction and endothelial swelling that block red blood cells from reaching capillaries, creating tissue-level “pseudo-hypoxia” despite normal pulse oximetry; mitochondria then shift to low-yield anaerobic metabolism with more inflammatory byproducts.
Red/near-infrared light (photobiomodulation) complements EWOT by increasing mitochondrial oxygen demand and efficiency (e.g., cytochrome c oxidase effects) and by promoting nitric oxide–mediated vasodilation, improving energy production and microvascular function.
Stacking protocol: complete a 15-minute EWOT session, then immediately apply red/near-IR light (10–15 minutes) to capitalize on elevated circulation and oxygen availability; simultaneous use is possible but less practical.
Discussed benefits include improved energy, sleep, pain, skin quality, recovery, and potential support in conditions with microvascular/mitochondrial dysfunction (e.g., Lyme, post-viral/long-COVID lungs), along with practical access to home EWOT systems and broad-spectrum red/IR devices.
Clinical Insight
Tissue hypoxia from microvascular and endothelial dysfunction can persist with normal SpO2 and underlies many chronic symptoms; combining strategies that enhance oxygen delivery (EWOT) with those that increase mitochondrial oxygen utilization and nitric oxide–driven vasodilation (red/near-IR light) may restore cellular energy and improve function in select patients.
Actionable Takeaway
For appropriately screened patients, implement a stack 3–5 times weekly: 15 minutes of EWOT at moderate exertion using a reservoir-fed concentrator (~93% O2), followed immediately by 10–15 minutes of red/near-IR photobiomodulation directed to priority regions (e.g., thorax for lung issues or large muscle groups); track response via symptoms (energy, sleep, pain) and, when available, vascular metrics (e.g., pulse wave velocity).
21. The Human Upgrade: Biohacking for Longevity & Performance
The Strangest Thing I Do Every Morning for 15 Minutes | Brad Pitzele : 1458
Published: 2026-04-30
URL: Listen Here
Summary
This episode explains how EWOT and red/near‑infrared light therapy can be combined to address mitochondrial dysfunction and microcirculatory ‘pseudo-hypoxia’ that underlie many chronic symptoms. The discussion emphasizes endothelial health, nitric oxide–mediated vasodilation, arterial stiffness (pulse wave velocity), and the lung’s role in detoxification, offering a practical sequencing strategy (EWOT, then PBM) to enhance energy, recovery, and tissue oxygenation. Limitations: the conversation is expert opinion–heavy and promotional in parts, and does not cite specific peer‑reviewed studies.
Key Takeaways
Exercise with oxygen therapy (EWOT) uses a concentrator and large reservoir (~93% O2) to deliver high oxygen flow during 10–15 minutes of moderate exercise, leveraging exercise-induced vasodilation and pressure gradients to drive oxygen deeper into tissues.
Stacking red/near-infrared photobiomodulation (PBM) immediately after EWOT exploits elevated circulation and oxygen availability to increase mitochondrial oxygen demand and efficiency, enhancing energy production, recovery, pain relief, and potentially sleep, skin, and sexual function via nitric oxide signaling.
Endothelial health and microcirculation are central: inflammation causes endothelial swelling and reduced RBC deformability, creating ‘pseudo-hypoxia’ (normal SpO2 but poor tissue oxygenation) that shifts mitochondria to inefficient anaerobic metabolism and a pro-inflammatory ‘doom loop.’
Arterial stiffness is an aging biomarker (e.g., pulse wave velocity); exercise and PBM can increase nitric oxide, improve vasodilation, and may support arterial flexibility and downstream tissue oxygenation.
Lungs are major detox organs (~70% of toxin elimination); adequate oxygen is required for biotransformation and repair. EWOT may support recovery in post-viral/lung injury states by improving cellular oxygenation and mitochondrial energy needed for healing.
Clinical Insight
Sequenced therapy—EWOT to rapidly elevate tissue oxygen supply followed immediately by PBM to raise mitochondrial oxygen demand—can help overcome tissue-level ‘pseudo-hypoxia,’ restore aerobic metabolism, and improve microcirculatory function in patients with chronic inflammation, endothelial dysfunction, or post-illness fatigue.
Actionable Takeaway
Implement a clinic protocol: 10–15 minutes of EWOT (reservoir-fed ~93% O2) at moderate intensity (elevated HR/respiratory rate) followed within 5 minutes by 10–20 minutes of PBM (combined red ~630–680 nm and near-infrared ~800–1050 nm) targeted to symptomatic regions (e.g., thorax for lung, large muscle groups, or generalized exposure). Monitor SpO2/HR/BP, start with conservative dosing, and track outcomes (e.g., 6MWT, symptom scores, VO2 max trend, pulse wave velocity/microvascular assessments). Screen for photosensitizing meds and cardio-pulmonary contraindications.
22. The Human Upgrade: Biohacking for Longevity & Performance
Eat These Foods + Spices for 8 Weeks To Get 3 Years Younger | Kara Fitzgerald : 1461
Published: 2026-05-05
URL: Listen Here
Summary
This episode highlights clinical and mechanistic evidence that diet rich in methyl donors and polyphenols—supported by foundational lifestyle practices—can reverse epigenetic age within weeks, with nutrients doing the ‘heavy lifting.’ It also explores the frontier of Yamanaka factor biology and PRC2-linked ‘programmatic’ aging, proposing that select polyphenols may partially mimic reprogramming effects. Limitations include multimodal design (potential confounding), reliance on specific clocks, and that ‘Yamanaka mimetic’ strategies are largely preclinical.
Key Takeaways
An 8-week randomized controlled dietary and lifestyle program emphasizing methyl-donor foods and polyphenol-rich ‘methylation adaptogens’ reduced biological age by over three years on the Horvath epigenetic clock in healthy middle-aged men; subsequent analysis suggested nutrients—especially dense polyphenols—were the primary drivers.
The protocol featured 7–11 cups/day of fruits, vegetables, herbs, and spices; methylation-supportive foods (e.g., leafy greens, eggs, beets, liver); and included meditation, sleep hygiene, and exercise, with the control group’s exercise likely making exercise effects a wash.
Polyphenols (e.g., EGCG from green tea; culinary herbs like rosemary, oregano, marjoram, thyme; and targeted options like urolithin A) may modulate gene expression and epigenetic marks; supplements can layer on top of diet for therapeutic dosing, though diet provides synergistic ‘information’ not captured by single compounds.
Emerging work on Yamanaka factors and polycomb repressive complex 2 (PRC2) suggests a ‘programmatic’ component of aging; early evidence indicates caloric restriction and potentially select polyphenols could act as ‘Yamanaka mimetics’ to nudge youthful epigenetic programs (largely preclinical at present).
First-generation clocks (e.g., Horvath) may capture aspects of programmatic aging; newer measures (e.g., DunedinPACE) are useful for tracking pace of aging. Case reports indicate women can also achieve meaningful bioage improvements with similar nutrition-forward protocols.
Clinical Insight
A targeted, food-first intervention emphasizing methyl-donor nutrients and high–polyphenol intake—augmented by basic lifestyle practices—can measurably and rapidly lower epigenetic age; in this cohort, the nutritional components appeared to account for most of the effect.
Actionable Takeaway
Implement an 8-week methylation-supportive nutrition plan (7–11 cups/day of diverse plants and polyphenol-rich herbs/spices; plus methyl donors like leafy greens, eggs, beets, and liver), alongside meditation and sleep hygiene; consider layering targeted polyphenol and metabolic supplements (e.g., EGCG, urolithin A, alpha‑ketoglutarate, sodium butyrate) as appropriate, and measure epigenetic age (e.g., Horvath/DunedinPACE) pre- and post-intervention to assess impact.
23. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
Dr. Casey Halpern outlines how compulsive behaviors arise from dysregulated cortico-striatal reward circuits and how neuromodulation—DBS, TMS, and MRgFUS—can be leveraged to treat refractory cases, with immediate efficacy in movement disorders and growing promise in psychiatry. The episode emphasizes personalized, symptom-evoked targeting and the integration of invasive recordings, noninvasive tools, and machine learning to advance precision therapies for OCD, addiction, and eating disorders.
Key Takeaways
Deep brain stimulation (DBS) and MR-guided focused ultrasound (MRgFUS) can precisely modulate small brain regions; DBS provides adjustable electrical therapy via implanted electrodes, while MRgFUS enables incisionless ablation—both are highly effective for tremor and are being explored for psychiatric indications.
Obsessive-compulsive disorder (OCD) involves dysregulation of cortico-striatal circuits, especially the ventral striatum/nucleus accumbens, which gate reward-seeking versus compulsive behaviors; similar circuitry underlies addiction and binge-eating.
First-line OCD treatments include SSRIs/tricyclics and exposure and response prevention (ERP) therapy; about 30% remain symptomatic, and in severe refractory cases, DBS or capsulotomy yields roughly 50% response rates but often with residual symptoms—highlighting the need for more precise, symptom-specific targeting.
Noninvasive neuromodulation is advancing: TMS is FDA-approved for depression, OCD, and nicotine addiction; MRgFUS is FDA-approved for essential tremor and tremor-dominant Parkinson’s disease, with research into modulatory ultrasound and blood–brain barrier opening; stereo-EEG (sEEG) is being leveraged to define better targets for psychiatric diseases.
Emerging approaches seek to detect and interrupt pathologic urges (e.g., craving/obsession cells) using intraoperative recordings, lab-based mood/craving provocation paradigms, and machine learning—aiming for closed-loop, personalized interventions; awareness helps less severe cases but is often insufficient for the most refractory patients.
Clinical Insight
Compulsive behaviors across OCD, addiction, and binge-eating share a core dysfunction in ventral striatal reward/limbic circuits (notably the nucleus accumbens); targeted and personalized circuit modulation—guided by symptom-evoked neural signatures—offers a path to improve outcomes beyond current ~50% response rates from conventional DBS/lesional approaches.
Actionable Takeaway
For patients with OCD who remain symptomatic after adequate SSRI/tricyclic trials and ERP, refer to a specialized neuromodulation center to evaluate FDA-cleared transcranial magnetic stimulation (TMS) for OCD and to discuss candidacy and expectations for investigational DBS/capsulotomy in severe, treatment-refractory cases.
24. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
This episode outlines how compulsive behaviors and OCD arise from dysregulated cortico–striatal–limbic circuits and how neuromodulation—from TMS to DBS and MRI-guided focused ultrasound—is being applied and refined to treat severe, refractory cases. It emphasizes circuit-specific targeting (e.g., ventral striatum/nucleus accumbens), closed-loop detection of craving/obsession signals, and the roles of ERP and pharmacotherapy as first-line treatments. Note: As an Essentials excerpt, procedural details and specific trial outcomes are summarized at a high level.
Key Takeaways
Deep brain stimulation (DBS) delivers targeted electrical stimulation via implanted leads; transient effects (e.g., brief laughter or panic) reveal proximity to limbic circuits and have informed psychiatric applications beyond movement disorders.
Obsessive-compulsive disorder (OCD) and related compulsive/impulsive syndromes involve hyperactive prefrontal/orbitofrontal regions and ventral striatal circuits (notably the nucleus accumbens) that gate reward and compulsion; circuit-informed targeting is central to therapy development.
First-line OCD care includes SSRIs or clomipramine (tricyclics) and exposure and response prevention (ERP); ~30% remain refractory, and current surgical options (DBS or capsulotomy) achieve about a 50% responder rate, with residual symptoms common.
Noninvasive neuromodulation is advancing: TMS is FDA-cleared for depression, OCD, and smoking cessation; MRI-guided focused ultrasound is FDA-approved for tremor and is being explored for modulatory (non-ablative) applications and potential psychiatric targets.
Closed-loop paradigms combining invasive recordings (e.g., stereo-EEG/DBS) with symptom or mood provocation can identify ‘craving/obsession’ signals (e.g., for binge eating) to personalize stimulation, while awareness-based therapies help many but often fail in the most severe, treatment-resistant cases.
Clinical Insight
Compulsive and impulsive disorders are circuit-based conditions of cortico–striatal–limbic networks; precise, and increasingly closed-loop, neuromodulation targeting the ventral striatum/nucleus accumbens can provide meaningful benefit for severe, treatment-resistant patients, while TMS offers an FDA-cleared, less invasive option for select indications.
Actionable Takeaway
Establish a referral pathway to a specialty center (functional neurosurgery/psychiatry) for patients with treatment-refractory OCD to discuss neuromodulation options—offer an FDA-cleared TMS trial first when available, and consider DBS or capsulotomy evaluation (or clinical trials) if nonresponsive.
25. The Human Upgrade: Biohacking for Longevity & Performance
Pandemic Fever Is BACK, Testosterone and Brain Tumors, Rabies, and Dog Flu : 1463
Published: 2026-05-08
URL: Listen Here
Summary
This episode synthesizes emerging signals in oncology and infectious disease: new data suggesting physiologic testosterone may restrain glioblastoma behavior, alongside multiple zoonotic threats (Influenza D, canine coronavirus HuPn-2018, Andes hantavirus) and a temporary disruption to U.S. rabies testing. The unifying message is proactive risk management—know patients’ biologic baselines (e.g., hormones), reinforce first-line defenses (mucosal immunity, sleep, stress), and act quickly when exposure windows are short (rabies, hantavirus).
Key Takeaways
NIH-funded Cleveland Clinic research reported that low testosterone may drive glioblastoma stemness and invasion, whereas restoring physiologic testosterone reduced tumor growth by ~38% and improved survival in models—challenging assumptions that lower androgens universally reduce cancer risk.
CDC has paused certain testing (including rabies), creating potential 1–2 week diagnostic delays; because rabies PEP is time-critical, suspected exposures warrant same-day ER initiation of prophylaxis without waiting for lab confirmation; ensure pets are vaccinated and consider pre-exposure prophylaxis when traveling to endemic regions.
A U.S. Supreme Court one-week stay preserved telehealth access to mifepristone pending rapid review; the legal reasoning could set precedents affecting FDA authority, telehealth, and access to therapies such as compounded peptides and bioidentical hormones.
University of Florida researchers highlighted two zoonotic risks: Influenza D circulating in U.S. cattle and a canine coronavirus (HuPn-2018) that has jumped to humans; no vaccines exist and population immunity is minimal—reassess raw milk risk and reduce close pet-lick exposure while strengthening mucosal immunity (sleep, stress control, vitamin D, zinc, fermented foods).
Andes hantavirus cases linked to a cruise ship off the Canary Islands underscore that this American strain can spread person-to-person and causes severe pulmonary syndrome with high case fatality; recognize early symptoms (fever, myalgias, abrupt fatigue) and pursue urgent evaluation after plausible exposure.
Clinical Insight
Maintaining normal physiologic testosterone may suppress glioblastoma aggressiveness by limiting tumor stemness and invasion, suggesting clinicians should consider comprehensive hormonal assessment—especially in men—when evaluating brain tumor biology and overall oncologic risk, while recognizing these are emerging data that do not alone warrant changes to standard cancer therapy without oncology guidance.
Actionable Takeaway
For any patient with a credible rabies exposure (e.g., bat contact, wild carnivore bite), initiate post-exposure prophylaxis immediately and do not wait for laboratory confirmation—verify current turnaround times at your state lab and proactively counsel patients traveling to endemic regions about pre-exposure vaccination and prompt care-seeking.
26. Huberman Lab
Essentials: Compulsive Behaviors & Deep Brain Stimulation | Dr. Casey Halpern
Published: 2026-05-07
URL: Listen Here
Summary
This episode reviews how neurosurgical and noninvasive neuromodulation tools can modulate cortico–striatal–limbic circuits driving compulsive and impulsive behaviors, with a focus on OCD, addiction, and binge eating. It emphasizes current standards (SSRIs/tricyclics and ERP), the limitations of outcomes in severe, refractory cases, and the promise of symptom-locked, circuit-guided targeting—potentially enabling future noninvasive, scalable treatments.
Key Takeaways
Deep brain stimulation (DBS) and MR-guided focused ultrasound (MRgFUS) can rapidly and powerfully modulate brain circuits; while established for tremor and Parkinson’s disease, these tools are being adapted to target limbic circuits implicated in compulsive and impulsive behaviors (e.g., OCD, addiction, binge eating).
OCD is best understood along a spectrum; first-line treatments include SSRIs/tricyclics and exposure and response prevention (ERP), yet ~30% remain refractory. For severe cases, DBS or capsulotomy yield about a 50% responder rate, often with residual symptoms—highlighting the need for more precise, symptom-locked targeting.
Compulsion and impulsivity share cortico-striatal-limbic circuitry (prefrontal/orbitofrontal cortex to basal ganglia/ventral striatum, especially nucleus accumbens) that gates reward seeking; identifying ‘craving/obsession-related’ neural signals intraoperatively and in lab paradigms is enabling symptom-specific neuromodulation.
Noninvasive neuromodulation is expanding: TMS is FDA-approved for depression, OCD, and nicotine addiction; MRgFUS is FDA-approved for tremor and is being explored for circuit modulation and blood–brain barrier opening. Stereo-EEG methods from epilepsy are informing circuit mapping for psychiatric indications to guide future noninvasive targets.
Improving patient awareness can help, but the most severe patients often remain refractory despite high awareness; combining rigorous circuit-guided neuromodulation with behavioral therapies and exploring AI/digital phenotyping to forecast high-risk states may provide scalable, clinically meaningful advances.
Clinical Insight
Compulsive and impulsive behaviors frequently arise from dysregulation within a shared cortico–striatal–limbic circuit—particularly the ventral striatum/nucleus accumbens—and targeted, symptom-linked neuromodulation (invasive now, potentially noninvasive later) can acutely alter these states, offering a path forward for patients with severe, treatment-resistant OCD and related conditions.
Actionable Takeaway
For patients with moderate-to-severe, treatment-resistant OCD (failed adequate SSRI/clomipramine trials and ERP), discuss risks/benefits and refer to a specialty center for consideration of neuromodulation—TMS (therapeutic and circuit-probing), DBS (e.g., ventral capsule/ventral striatum) or capsulotomy—and potential enrollment in circuit-mapping/SEEG-informed trials, while maintaining evidence-based behavioral therapy.
27. The Human Upgrade: Biohacking for Longevity & Performance
Pandemic Fever Is BACK, Testosterone and Brain Tumors, Rabies, and Dog Flu : 1463
Published: 2026-05-08
URL: Listen Here
Summary
This episode synthesizes timely health stories: a Cleveland Clinic/NIH report that normal testosterone may suppress glioblastoma stemness, a CDC testing pause that heightens urgency for immediate rabies PEP, legal moves affecting mifepristone telehealth access, and zoonotic threats from influenza D, canine coronavirus, and Andes hantavirus. The unifying theme is proactive risk management—optimizing hormonal and immune baselines and taking swift action after high-consequence exposures. Some details are host-reported and specific study links were not provided in-episode, which may limit independent verification.
Key Takeaways
NIH-funded Cleveland Clinic research reported that physiologic testosterone suppresses glioblastoma stemness and invasion; in models, restoring normal T reduced tumor growth by ~38% and improved survival—challenging the assumption that lower testosterone uniformly lowers cancer risk.
The CDC pause in rabies (and some other) testing is causing 1–2 week diagnostic delays; because post-exposure prophylaxis (PEP) must start promptly (≈10 days) and symptomatic rabies is nearly 100% fatal, suspected exposures warrant same-day ER care, with pets kept current on vaccines and travelers to endemic regions considering pre-exposure prophylaxis.
A temporary U.S. Supreme Court stay preserved mail/telehealth access to mifepristone pending further action—raising broader implications for courts influencing FDA-approved protocols and telehealth access across other therapies (e.g., compounded peptides, bioidentical hormones).
University of Florida researchers flagged two zoonotic risks: influenza D circulating in U.S. cattle and a canine coronavirus strain (CCoV-HuPn-2018) previously detected in humans; neither has established population immunity or vaccines, underscoring practical steps to bolster mucosal immunity and apply caution with raw milk and close pet contact (e.g., face-licking).
An outbreak of Andes hantavirus linked to a cruise near the Canary Islands highlights that this strain can spread person-to-person and causes severe HPS with high mortality; early symptoms (fever, myalgias, rapid-onset fatigue) after plausible exposure should prompt urgent evaluation and explicit hantavirus consideration.
Clinical Insight
Emerging evidence suggests hypogonadism may promote glioblastoma aggressiveness via androgen receptor signaling; in appropriate male patients, clinicians should assess total and free testosterone and avoid non-indicated androgen deprivation—coordinating closely with oncology before modifying cancer-related hormonal management.
Actionable Takeaway
For suspected rabies exposures (e.g., bat contact/bites), initiate CDC-recommended post-exposure prophylaxis immediately without waiting for laboratory confirmation, given current testing delays and the near-100% fatality once symptoms begin.
28. Huberman Lab
Essentials: Understanding & Controlling Aggression
Published: 2026-05-14
URL: Listen Here
Summary
This episode explains the neural circuitry of aggression, emphasizing VMHvl Esr1+ neurons and how aromatized estrogen, stress hormones, and photoperiod interact to gate aggressive behaviors. It reframes testosterone’s role, highlights rapid circuit-level switches between mating and attack, and offers practical strategies—light exposure, heat, selective supplementation—to modulate aggression. As an Essentials recap, some dosing specifics and full trial details are referenced from prior episodes or literature rather than provided exhaustively in-audio.
Key Takeaways
Aggression comprises distinct forms (reactive, proactive, indirect) and is generated by coordinated neural circuits—most critically estrogen receptor–expressing neurons in the ventromedial hypothalamus (VMHvl)—acting as fixed action patterns rather than isolated brain regions.
Testosterone does not directly cause aggression; its aromatization to estrogen within the brain activates VMHvl Esr1+ neurons to drive attack behaviors in both males and females.
Context strongly gates aggression: short photoperiods, elevated cortisol, and low serotonin increase the likelihood that estrogen will trigger aggression; long photoperiods (more daylight) mitigate this effect via changes in melatonin, dopamine, and stress hormones.
Optogenetic activation of VMHvl Esr1+ neurons can rapidly switch behavior (e.g., from mating to attack) and recruits downstream periaqueductal gray (PAG) circuits that organize motor patterns such as biting and limb striking.
Practical levers to reduce aggressive tendencies include lowering cortisol (morning sunlight exposure, sauna/hot baths; cautious, short-term ashwagandha) and, in ADHD, adjunct acetyl-L-carnitine has evidence for reducing aggressive/impulsive episodes in a randomized controlled trial.
Clinical Insight
Aggression propensity is a state-dependent output of hypothalamic circuits (VMHvl Esr1+), gated by steroid signaling and the stress–neurochemical milieu; assessing and modulating contextual factors—especially cortisol/photoperiod and serotonergic tone—can meaningfully alter aggressive behavior beyond simplistic attributions to testosterone or mood states.
Actionable Takeaway
Implement a structured morning light protocol for irritable or seasonally worsened aggression: advise 10–30 minutes of outdoor sunlight exposure within 1 hour of waking, daily for 2–4 weeks, to lower cortisol and shift neuromodulators toward reduced reactivity; reassess symptoms and add heat therapy (e.g., 20-minute sauna or hot bath sessions) as needed.
29. The Human Upgrade: Biohacking for Longevity & Performance
Semen Switch, Chewing Gum, Creatine Cheat, Cancer Plants, and Bedtime Risk : 1467
Published: 2026-05-15
URL: Listen Here
Summary
This episode reviews studies on creatine’s cognitive support under acute sleep loss, microplastic exposure from chewing gum, the cardiovascular risks of irregular bedtimes, plant alkaloid biosynthesis enabling anticancer drug discovery, and a reversible nonhormonal male contraceptive target. The unifying theme is that seemingly neutral habits or exposures can carry measurable biological effects, with particular clinical relevance for circadian consistency. Limitations: the transcript lacks formal citations and may contain transcription errors in compound or organism names; verify primary sources before changing practice.
Key Takeaways
A single moderate dose of creatine (~14 g) preserved up to ~12% more cognitive performance during 21 hours of sleep deprivation in a double-blind crossover trial; women and people with lower baseline brain creatine (e.g., vegetarians/vegans) appeared to benefit more.
Chewing gum (synthetic and products marketed as natural/plastic-free) shed hundreds to ~3,000 microplastic fragments per stick into saliva; detected polymers included polyethylene and polystyrene, highlighting a previously underrecognized exposure source.
Objectively measured irregular bedtimes combined with shorter sleep were associated with about double the risk of major cardiovascular events over a decade in a Finnish cohort, underscoring the clinical importance of sleep timing regularity.
UBC researchers mapped a chromosome-level genome and decoded the biosynthetic pathway for a rare spirooxindole alkaloid (Mitraphylene) implicated in anti-tumor and anti-inflammatory activity, enabling potential scalable bioproduction; this is an early-stage drug discovery lead, not a recommendation to use kratom or related supplements.
Cornell researchers demonstrated reversible, nonhormonal male contraception in mice by inhibiting the testis-specific protein BRDT with JQ1: spermatogenesis stopped during treatment and fertility recovered after cessation with healthy offspring; translational safety and long-term effects require further study.
Clinical Insight
Sleep regularity—not just duration—is a modifiable risk factor linked to major cardiovascular events; counseling patients to maintain consistent bedtimes should be incorporated into cardiovascular risk reduction strategies.
Actionable Takeaway
Ask patients to set and adhere to a fixed 90-minute bedtime window every day (including weekends) and reassess sleep timing variability after 4–8 weeks; for higher-risk individuals, consider actigraphy or validated wearable data to quantify and address irregularity.
30. The Human Upgrade: Biohacking for Longevity & Performance
Semen Switch, Chewing Gum, Creatine Cheat, Cancer Plants, and Bedtime Risk : 1467
Published: 2026-05-15
URL: Listen Here
Summary
This episode reviews new research spanning acute creatine use for sleep-deprivation resilience, unrecognized microplastic exposure from chewing gum, the cardiovascular risks of irregular sleep timing, plant-derived drug discovery via kratom alkaloid biosynthesis, and a reversible, non-hormonal target for male contraception. The themes emphasize measurable exposures and behaviors that affect health now (e.g., sleep regularity, microplastics) and pipeline advances likely to influence future oncology and reproductive therapeutics.
Key Takeaways
Acute creatine supplementation (~10–15 g monohydrate) preserved up to ~12% more cognitive performance during 21 hours of sleep deprivation in a double-blind crossover trial; benefits appeared greater in women and those with lower baseline brain creatine (e.g., vegetarians/vegans).
Chewing gum—both synthetic and products marketed as “natural” or “plastic-free”—shed hundreds to ~3,000 microplastic fragments per stick into saliva during chewing, adding a largely unrecognized exposure source.
Objectively measured irregular bedtimes combined with short sleep duration were associated with approximately double the risk of major cardiovascular events over a decade, underscoring circadian regularity as a modifiable risk factor.
UBC researchers mapped the genome of Mitragyna parvifolia and decoded the biosynthetic pathway for the alkaloid mitraphylline, enabling potential bioreactor-scale production; this is a drug discovery pipeline advance, not evidence that kratom treats cancer.
Pharmacologic inhibition of the testis-specific protein BRDT with JQ1 in mice produced a reversible, non-hormonal “on–off” switch for spermatogenesis, restoring fertility after treatment cessation and suggesting a viable target for male contraception.
Clinical Insight
Sleep timing regularity is an independent, modifiable cardiovascular risk factor: patients with highly irregular bedtimes and short sleep had roughly double the rate of major cardiovascular events when sleep timing was objectively measured, supporting routine assessment and counseling on circadian consistency.
Actionable Takeaway
Incorporate a brief sleep-timing screen (e.g., ask about bedtime variability and weekend ‘social jetlag’) and counsel patients to maintain a consistent 90-minute bedtime window across all days, including weekends, as part of cardiovascular risk reduction.
31. Huberman Lab
How to Overcome Social Anxiety | Dr. Nick Epley
Published: 2026-05-18
URL: Listen Here
Summary
Evidence converges that small, authentic social exchanges meaningfully improve mental and physical well-being. Social anxiety is best treated with real-world exposure that recalibrates overly pessimistic beliefs about others. Voice and in-person modalities humanize and increase perceived intelligence relative to text, suggesting clinicians and clients should favor voice/in-person touchpoints when feasible.
Key Takeaways
Real-world social exposure—not simulation—reduces social anxiety by updating inaccurate predictions about rejection; people are helped and accepted more often than they expect.
Brief, everyday interactions (greetings, small talk, sincere compliments) reliably lift mood; the biggest well-being gain comes from moving from no contact to some contact.
Voice conveys rich mental-state cues that humanize others; compared with text, speaking increases perceived intelligence and mutual understanding, especially across divides.
We routinely misread others due to cognitive biases (egocentrism, stereotyping, correspondence bias); testing assumptions through low-stakes bids to connect corrects many misinferences.
Short periods of acting more extraverted increase positive affect for most people, including introverts; small, repeated real interactions function as effective ‘social prescriptions’.
Clinical Insight
Loneliness and social isolation are modifiable risk factors linked to increased all-cause mortality, cardiometabolic burden, and dysregulated stress physiology. For social anxiety, graded in vivo exposure is an evidence-based intervention that changes maladaptive social predictions (e.g., overestimating rejection) rather than merely dampening arousal.
Actionable Takeaway
Implement a 2-week graded social exposure plan: daily, initiate one brief, real interaction (e.g., greet a neighbor or cashier, ask a small favor, offer a sincere compliment); log predicted outcome vs. actual outcome to capture expectancy violations. Each week, add 2–3 short voice calls (not texts) to trusted contacts. Progressively increase depth or duration as mispredictions correct.
32. Huberman Lab
How to Overcome Social Anxiety | Dr. Nick Epley
Published: 2026-05-18
URL: Listen Here
Summary
Dr. Nick Epley discusses how everyday social connections—especially those using richer cues like voice and eye contact—improve mental and physical health, and how misbeliefs about others’ interest create avoidant behavior and social anxiety. He outlines evidence that real-world exposure updates these misbeliefs, highlights the health costs of isolation, and offers practical ways to cultivate frequent, small interactions that enhance well-being.
Key Takeaways
Real-world exposure (not simulation) is the most effective way to reduce social anxiety because it updates mistaken beliefs about rejection and others’ responses.
People reliably underestimate how much others want to engage and help; silence and phone use are often misread as disinterest, leading to missed opportunities for connection.
Richer communication channels—especially voice (and eyes/visual behavior when available)—convey the ‘presence of mind,’ reduce dehumanization, and improve mutual understanding compared with text-only exchanges.
Small, daily social interactions (brief greetings, compliments, short conversations) measurably improve mood and health; moving from no contact to some contact yields the biggest well-being gains.
Acting more extroverted (within one’s comfort) increases positive affect across the introversion–extroversion spectrum; building simple, repeatable social habits is key.
Clinical Insight
For patients with social anxiety, the core therapeutic lever is belief change achieved through graded, in vivo exposure to real social interactions—patients learn (through experience) that positive or neutral responses are far more common than anticipated, which reduces avoidance and improves functioning.
Actionable Takeaway
Prescribe a graded real-world exposure plan: ask the patient to complete one brief, low-stakes social action daily (e.g., greet a stranger, ask for minor help, offer a sincere compliment), log the outcome, and review weekly to challenge overestimated rejection fears and reinforce corrective learning.
33. The Human Upgrade: Biohacking for Longevity & Performance
The Biblical Anti-Aging Fruit That Scientists Are Obsessed With : 1470
Published: 2026-05-21
URL: Listen Here
Summary
This episode details the discovery-to-clinic journey of urolithin A (Mitopure) as a nutritional mitophagy activator that enhances mitochondrial function, with human data showing improved immune cell composition and mitochondrial gene expression after 4 weeks and topical studies demonstrating better collagen signaling and wrinkle reduction. It provides dosing guidance and highlights the limitations of pomegranate-derived precursors, underscoring UA’s relevance for clinicians integrating mitochondrial-targeted interventions into healthy aging care.
Key Takeaways
Urolithin A (Mitopure), a gut-derived postbiotic from pomegranate ellagitannins, activates mitophagy and improves mitochondrial function; preclinical work showed ~45% lifespan extension in C. elegans and ~40% endurance gains in aged mice.
In a human study (Nature Aging), adults aged 50–70 taking 1 g/day for 4 weeks had increased naïve CD8 T cells and NK cells, decreased inflammation, and upregulated mitochondrial gene expression/function in immune cells.
Muscle biopsy studies show increased expression of mitochondrial genes after 4 weeks of oral urolithin A at 500–1,000 mg/day, helping define an effective daily dose (≥500 mg) for clinical use.
Topical urolithin A improved skin biology and appearance: increased collagen-related gene expression, >10% reduction in UV-induced inflammation, and statistically significant wrinkle reduction by 8 weeks (signals as early as 2 weeks).
Only ~30–40% of people can convert pomegranate polyphenols into urolithin A; direct UA supplementation provides reliable exposure versus juice/extracts (which also add sugar/oxalates).
Clinical Insight
Urolithin A is an evidence-based mitophagy activator with early clinical signals in muscle and immune aging; consistent supplementation (≥500 mg/day) can improve mitochondrial-related biomarkers and immune cell profiles in midlife and older adults, offering a practical adjunct for healthy aging strategies.
Actionable Takeaway
For eligible adults focused on longevity or mitochondrial health, consider urolithin A 500 mg daily (up to 1,000 mg) taken consistently for 2–4 months before assessing response; avoid relying on pomegranate extracts due to variable microbiome conversion, and optionally pair with topical UA for skin benefits.
34. The Human Upgrade: Biohacking for Longevity & Performance
The Biblical Anti-Aging Fruit That Scientists Are Obsessed With : 1470
Published: 2026-05-21
URL: Listen Here
Summary
This episode details the discovery-to-clinic journey of urolithin A as a mitophagy activator that targets a root mechanism of aging: mitochondrial dysfunction. The discussion reviews preclinical and human data showing improvements in muscle mitochondrial gene expression, immune cell composition, and topical skin outcomes, positioning urolithin A as a practical, evidence-supported addition to longevity care. (Note: Some study specifics were summarized at a high level in the transcript and may lack full methodological details.)
Key Takeaways
Urolithin A (commercialized as Mitopure/Timeline) is a postbiotic derived from pomegranate ellagitannins via gut microbes; only ~30–40% of people naturally convert, so a standardized supplement ensures reliable delivery at effective doses.
Mechanism of action is mitophagy activation (selective recycling of dysfunctional mitochondria), with preclinical data showing ~45% lifespan extension in C. elegans and ~40% greater running endurance in aged mice.
Human data: 4 weeks of 500 mg–1 g/day increased mitochondrial gene expression in skeletal muscle biopsies; clinical benefits are most apparent with consistent daily use over 2–4 months.
Immune health (Nature Aging study): adults aged 50–70 taking 1 g/day for 1 month had increased naive CD8 T cells and NK cells and reduced inflammatory signaling.
Topical urolithin A increased collagen-related gene expression, reduced post-UV skin inflammation (~10%), and produced statistically significant reductions in fine lines/wrinkles by 8 weeks; L’Oréal is collaborating to incorporate the ingredient based on shared research.
Clinical Insight
Standardized urolithin A is a clinically investigated mitophagy activator that can improve mitochondrial biomarkers and favorably shift immune cell populations in older adults within weeks, supporting its use as a safe, adjunctive tool to enhance healthspan beyond traditional approaches (e.g., NAD precursors, rapamycin).
Actionable Takeaway
For adults over ~50, consider a monitored 8–12 week trial of urolithin A at 500–1000 mg orally once daily; track patient-reported energy/exercise tolerance and optionally inflammation markers (e.g., CRP) or simple functional tests, and avoid substituting pomegranate extract due to variable microbiome conversion.
35. Huberman Lab
Build Muscle, Great Posture & Resilience to Injury | Jeff Cavaliere
Published: 2026-05-25
URL: Listen Here
Summary
This episode emphasizes that “small” accessory work—especially for the glute medius, rotator cuff, neck, grip, and feet—makes the big lifts possible for decades by preventing pain and improving function. Cavaliere outlines practical screens (e.g., old‑man shoe/sock test) and brief, low‑equipment drills that clinicians and trainees can integrate alongside flexible programming and sensible nutrition to support long‑term health, performance, and injury resilience.
Key Takeaways
Small, often-neglected muscles and motor control (glute medius, rotator cuff, neck flexors/extensors, foot intrinsics) are foundational for pain-free longevity and enable progress on the big compound lifts.
A large share of nonsurgical low back pain reflects gluteal weakness and pelvic control deficits (e.g., Trendelenburg pattern) rather than spine pathology; targeted work (reverse hypers, wall ‘hip hike,’ banded hip rotation) can resolve symptoms and prevent recurrence.
Medial elbow pain during pulling is frequently a grip/hand position issue (overloading ring/pinky at the fingertips); using a knuckles-over-bar grip and loading the meat of the hand often eliminates symptoms.
Shoulder durability depends on external rotator strength and posture—train banded external rotation with the elbow pinned (towel cue), use face pulls, and avoid chronically elevated, internally rotated positions.
Programming principles: take safer/isolation movements to (or near) failure, avoid true failure on complex lifts, count indirect volume (e.g., biceps on back day), and use flexible scheduling (even ‘split the split’) rather than forcing a 7‑day template; pair with simple daily/weekly function tests (old‑man shoe/sock test, side‑plank with top-leg abduction) and sensible ‘clean omnivore’ nutrition.
Clinical Insight
For many patients with common musculoskeletal complaints (e.g., nonspecific low back pain, shoulder impingement symptoms, medial elbow pain), the primary driver is often weakness or poor motor control in adjacent or distal links of the kinetic chain (glute medius/pelvic control, rotator cuff external rotators, grip mechanics) rather than structural pathology—prioritizing targeted strengthening and technique cues can reduce pain, restore function, and decrease unnecessary imaging or surgical referrals.
Actionable Takeaway
For chronic, nonspecific low back pain, screen glute medius function (single‑leg stance/Trendelenburg sign) and prescribe a 5–7 minute, 3x/week accessory routine: wall ‘hip hike’/abduction (2–3 sets/side) plus reverse hypers or prone hip extension with a brief hold at peak contraction (2–3 sets). Reassess gait and pain after 2–4 weeks and progress to banded hip ER/IR as tolerated.
36. Health Longevity Secrets
The Army Ranger Who Found Magic Mushrooms Save Lives — Neil Markey (Beckley Retreats)
Published: 2026-05-26
URL: Listen Here
Summary
This episode explores how meditation and professionally facilitated psilocybin experiences can synergize to regulate the nervous system, enhance neuroplasticity, and catalyze durable behavior change. It highlights safety, set/setting, integration, and the potential for preventative, population-level well-being—illustrated through the Beckley Retreats model and emerging research partnerships.
Key Takeaways
Professionally facilitated psilocybin experiences can transiently increase neuroplasticity, helping people ‘reset’ rigid cognitive and emotional patterns and adopt healthier habits—most effective when paired with structured preparation and post-session integration.
Meditation and psychedelics are complementary; baseline self-awareness and nervous-system regulation through mindfulness can enhance both the safety and the depth of psychedelic work.
Psilocybin has a favorable safety profile (non-toxic) when used with proper screening, dosing, and attention to set and setting; greater caution is warranted in severe psychiatric conditions, and skilled facilitation plus follow-up reduce risks.
Applications extend beyond treating pathology to preventative well-being—improving empathy, connectedness, sleep, relationships, and addressing burnout among high-functioning individuals.
Beckley Retreats delivers legal, non-clinical programs in Jamaica and the Netherlands with comprehensive preparation, facilitation, and integration; as a Public Benefit Corporation, it prioritizes access and outcomes and partners with academic groups (e.g., Harvard Chan School) for research.
Clinical Insight
Psilocybin, administered in a structured program with careful screening, set/setting, and integration, can open a short window of enhanced neuroplasticity that supports meaningful behavior change and symptomatic relief—suggesting utility as both an adjunct to care and a preventative tool when thoughtfully applied.
Actionable Takeaway
When patients express interest in psychedelic-assisted care, screen for red flags (e.g., severe psychiatric instability), and—where legal/available—refer to structured, professionally facilitated programs or clinical trials that include preparation and integration; advise beginning a simple daily mindfulness practice (e.g., 10 minutes of breath-focused meditation) for several weeks before any session.
37. The Human Upgrade: Biohacking for Longevity & Performance
The Doctor With Answers To Your Mystery Symptoms | Jessica Peatross : 1473
Published: 2026-05-26
URL: Listen Here
Summary
This episode frames many chronic, post-infectious, and environmental illness presentations through a functional lens centered on mast cell activation/histamine excess, low morning cortisol/low blood pressure, and biotoxin (mold) exposure. It emphasizes treatment sequencing (stabilize first, then treat), environmental testing, and practical tools (antihistamines, vagal support, enzymes, selective binders) for long-COVID and ‘mystery’ cases. Note: several assertions (e.g., vaccine-related claims, broad testing critiques) are controversial and not fully referenced in the discussion.
Key Takeaways
Mast cell activation and histamine dysregulation are presented as common, unifying drivers of multi-system ‘mystery’ symptoms—especially after COVID infection—manifesting in brain (racing thoughts, anxiety), heart (palpitations/POTS), gut (bloating/loose stools/GERD), skin (hives/eczema), bladder (IC), uterus (endometriosis), and in systemic anaphylactoid reactions.
Therapy sequencing matters: before anti-parasitic or aggressive detox protocols, stabilize the nervous system (vagal tone), replete minerals/electrolytes, and ensure elimination (daily bowel movements, sweating, bile flow) to minimize Herxheimer reactions and treatment intolerance.
Low morning cortisol and low blood pressure are underrecognized in chronically ill patients; supporting circadian cortisol rhythm and blood volume (e.g., salt and mineral intake, B vitamins, vagal support) can reduce ‘tired–wired’ cycling and orthostatic symptoms.
Environmental biotoxins—especially household/building mold—may underlie or mimic Lyme disease, ADHD-like symptoms, and other chronic complaints; targeted environmental assessment plus appropriate binders (chosen to match toxin profiles) are emphasized.
Long-COVID symptom management discussed includes H1/H2 antihistamine trials, vagal-nerve stimulation, nasal/nebulized mucosal therapies, and proteolytic enzymes (nattokinase/lumbrokinase); a potential role for nicotine and progesterone as mast-cell stabilizers is mentioned but remains controversial and not conventionally endorsed.
Clinical Insight
In patients with persistent, multi-system ‘mystery’ symptoms—particularly post-COVID—consider mast cell activation/histamine excess as a central mechanism; prioritize nervous-system regulation and mineral/volume repletion, ensure elimination pathways are open, and then use targeted interventions (e.g., antihistamines, mucosal care, cautious binders) rather than initiating aggressive pathogen-kill or detox first.
Actionable Takeaway
For patients with post-COVID, multi-system symptoms suggestive of mast cell activation, implement a structured 4–6 week therapeutic trial of non-sedating H1/H2 antihistamines alongside low-histamine nutrition and vagal-tone support, while repleting electrolytes/minerals and ensuring daily bowel movements—then reassess symptom change to guide next steps.
38. The Second Opinion Podcast with Dr. Paul Kolodzik
EP 120 GLP-1 News + Other fun medical facts.
Published: 2026-05-28
URL: Listen Here
Summary
This episode covers a potpourri of updates: evolving guidance on aspirin for primary prevention, rising persistence with GLP-1 therapies, and expanding evidence that GLP-1s reduce cardiovascular risk and may alleviate joint pain through anti-inflammatory and glycemic effects. The discussion emphasizes pairing GLP-1s with lifestyle strategies (strength training, carbohydrate moderation, adequate protein) and underscores that benefits may wane when therapy is stopped. Specific studies are referenced conceptually in the conversation without formal citations.
Key Takeaways
Daily aspirin is no longer broadly recommended for primary prevention of cardiovascular disease—especially in older adults—because bleeding risks often outweigh benefits; it remains standard for secondary prevention after myocardial infarction or stroke.
Real-world persistence with GLP-1 receptor agonists over 12 months has increased substantially since 2021, likely due to improved access, lower costs, and micro-dosing strategies.
GLP-1 therapies reduce cardiovascular events and stroke risk beyond weight loss, likely via glycemic stabilization and anti-inflammatory effects; discontinuation can attenuate these cardiometabolic benefits over time.
GLP-1 agents may lessen osteoarthritis/joint pain beyond weight effects, potentially through anti-inflammatory mechanisms, while weight reduction also decreases joint load.
For best outcomes, pair GLP-1 therapy with lifestyle measures—carbohydrate moderation, possible intermittent fasting, strength training, and adequate daily protein intake (e.g., ~100 g/day as discussed).
Clinical Insight
In contemporary practice, prioritize individualized risk–benefit assessments for aspirin in primary prevention (often avoiding it in older adults) and recognize that GLP-1 therapy provides cardiovascular risk reduction beyond weight loss that generally requires ongoing treatment and concurrent lifestyle optimization.
Actionable Takeaway
For patients aged ≥70 taking daily aspirin without prior ASCVD, schedule a medication review to reassess primary-prevention aspirin per current guidelines and consider deprescribing if bleeding risk outweighs benefit.
39. The Human Upgrade: Biohacking for Longevity & Performance
Combine Creatine With THIS To Fight The Root Cause of Aging | Andrew Salzman : 1474
Published: 2026-05-28
URL: Listen Here
Summary
This episode proposes that the root cause of aging may lie in progressive gut barrier failure that drives systemic inflammation, CD38 upregulation, and NAD depletion. Dr. Salzman outlines a dual approach: preserve NAD (precursors plus CD38/PARP modulation and targeted antioxidants) and improve energy distribution with creatine’s phosphocreatine shuttle, especially to the intestinal epithelium’s tight junctions. Practical steps include butyrate-focused diet, postprandial rest, and high-quality creatine; note that many claims were discussed conceptually and specific study citations were not provided in the transcript.
Key Takeaways
Dr. Andrew Salzman advances a unifying hypothesis that age-related systemic inflammation originates in progressive intestinal barrier failure: bacterial products (especially flagellin and LPS) cross weakened tight junctions, upregulate CD38, deplete NAD, and create a self-reinforcing cycle of “inflammaging.”
Sustaining NAD requires both supply and protection: precursors (e.g., NMN) should be paired with strategies that limit degradation (CD38 modulation, reduced PARP activation via less DNA damage) and targeted antioxidants/polyphenols (e.g., hydroxytyrosol, resveratrol, ergothionine; apigenin discussed for CD38).
Peroxynitrite—formed from superoxide and nitric oxide—is a particularly harmful oxidant; prevention focuses on reducing superoxide via mitochondrial health and antioxidant systems (SOD, glutathione) or using peroxynitrite decomposition catalysts, rather than indiscriminate high-dose general antioxidants.
Creatine’s key physiologic role is spatiotemporal ATP delivery via the phosphocreatine shuttle to high-demand microdomains (gut tight junctions, heart, brain synapses, fast-twitch muscle). Oral creatine (~3–5 g/day) can raise tissue creatine ~15–20% and may tighten gut junctions; avoid in significant renal impairment and use high-purity sources.
Clinical/lifestyle implications: allow 20–30 minutes of rest after meals to preserve gut perfusion/ATP, use fermentable fibers to increase butyrate (which tightens junctions), consider intermittent fasting/ketosis to support epithelial energetics, and view gut energetics as a central target for healthy aging.
Clinical Insight
Gut-barrier energetics may be a primary, modifiable driver of inflammaging: combining NAD-maintenance (precursor plus CD38/PARP modulation and targeted antioxidants) with creatine to enhance phosphocreatine-mediated ATP delivery can help preserve tight junction integrity, reduce translocation of bacterial products, and blunt systemic inflammatory signaling.
Actionable Takeaway
In adults without significant kidney disease, consider initiating high-purity creatine monohydrate 3–5 g orally once daily (no loading) to support phosphocreatine-mediated ATP delivery—particularly to intestinal tight junctions—and reassess GI symptoms and overall resilience over 4–6 weeks.
40. Health Longevity Secrets
EXPLAINER: The Blood Test Number That Predicts Mortality (And the FDA Drug That Moves It)
Published: 2026-05-28
URL: Listen Here
Summary
This episode explains why absolute lymphocyte count is a robust, underused mortality predictor and outlines how IL‑15 biology connects immune aging, senescence clearance, inflammation, and muscle health. It highlights the FDA-approved IL‑15 superagonist Anctiva/Anktiva for bladder cancer and weighs its theoretical potential—and current limitations—as a longevity intervention. The transcript references key studies and regulatory milestones but does not provide full bibliographic details.
Key Takeaways
Absolute lymphocyte count (ALC) on a routine CBC is a powerful, inexpensive predictor of all-cause and cause-specific mortality; lymphopenia is defined roughly as ALC <1500/µL (relative) and <1000/µL (severe).
Across three large cohorts (NHANES/JAMA Network Open 2019; Copenhagen General Population Study; post–coronary angiography cohort), lymphopenia was associated with markedly higher mortality (hazard ratios ~1.6–2.0) independent of common risk factors.
Combining ALC with RDW and CRP dramatically stratified 10-year mortality risk in NHANES (from <4% in the healthiest group to ~62% in the worst group).
Interleukin-15 (IL-15) expands/activates NK cells and CD8+ T cells without expanding Tregs (unlike IL-2), is released by contracting skeletal muscle (a myokine), and mechanistically links immunosenescence, senescent cell clearance, inflammation, and sarcopenia.
Anctiva/Anktiva (nogapendekin alfa inbakicept), an IL-15 superagonist, received FDA approval (April 2024) with BCG for BCG‑unresponsive non–muscle‑invasive bladder cancer; while mechanistically promising for longevity, there are no human longevity trials yet and immune activation carries risks.
Clinical Insight
Trending and contextualizing absolute lymphocyte count on routine CBCs can refine risk assessment; meanwhile, evidence-based levers that support lymphocyte and NK cell function—especially resistance training, adequate protein, sleep optimization, treatment of chronic infections/periodontitis, and reduction of visceral adiposity—are practical to implement while IL‑15 agonism remains investigational for longevity.
Actionable Takeaway
Start tracking ALC longitudinally in adult patients and, if it persistently falls below ~1500/µL, assess for reversible causes (e.g., chronic infection/inflammation, medications, malnutrition, sleep deficit, periodontal disease, visceral adiposity) and counsel on resistance training with adequate protein; consider hematology/immunology input for unexplained or severe lymphopenia (<1000/µL).
41. Huberman Lab
Essentials: The Science & Process of Healing from Grief
Published: 2026-05-28
URL: Listen Here
Summary
This episode explains the neuroscience of grief as remapping an attachment network that integrates space, time, and closeness, highlighting why yearning and prediction errors arise after loss. It outlines evidence-informed tools—attachment-focused, time-limited processing; vagal tone enhancement; and circadian/sleep optimization—to support neuroplastic adaptation and reduce complicated grief risk.
Key Takeaways
Attachments are encoded in an integrated neural map of space, time, and closeness; grief is the process of uncoupling the closeness (attachment) dimension from space and time predictions, with evidence implicating the inferior parietal lobule.
Grief and depression are distinct; despite overlapping symptoms, neuroimaging indicates grief prominently engages motivation/craving circuits (e.g., nucleus accumbens) and prediction processes.
Individual differences in yearning during grief likely relate to oxytocin signaling—particularly oxytocin receptor expression within motivation circuitry—supported by prairie vole and human studies.
Adaptive processing is facilitated by scheduled, time-limited ‘rational grieving’ that fully contacts the attachment while avoiding counterfactual (“what if”) rumination; expressive writing appears most helpful in those with higher vagal tone.
Stabilizing sleep and circadian biology (e.g., early daylight exposure) and increasing vagal tone (slow exhalation-focused breathing) support healthy grieving; late-day cortisol elevation associates with complicated grief, and sleep/NSDR help consolidate the neural remapping needed to progress through grief.
Clinical Insight
Grief recovery hinges on neuroplastic remapping of an integrated space–time–closeness attachment network; clinicians can improve outcomes by pairing attachment-focused processing (not avoidance) with autonomic and circadian stabilization to reduce risk for complicated grief.
Actionable Takeaway
Recommend a structured, daily 10–20 minute ‘rational grieving’ session in which the patient writes or reflects deeply on their attachment (avoiding counterfactuals) while practicing slow breathing (e.g., 4-second inhale, 6–8-second exhale) to raise vagal tone and enhance adaptive processing.
42. Huberman Lab
Essentials: The Science & Process of Healing from Grief
Published: 2026-05-28
URL: Listen Here
Summary
This episode reframes grief as a neurobiological remapping process across space, time, and closeness, emphasizing that yearning arises from motivation circuits rather than depression per se. It offers practical, physiology-informed tools—structured grieving sessions, vagal tone enhancement, and sleep/cortisol stabilization—to support adaptive progression through grief and reduce risk of complicated grief. Some imaging findings and animal-to-human links were discussed without full study citations in the episode.
Key Takeaways
The brain maps relationships across three braided dimensions—space, time, and closeness—and grief is the neuroplastic remapping that uncouples space/time predictions from an intact sense of attachment.
fMRI work highlights the inferior parietal lobule as a common code for physical distance, temporal spacing, and social closeness, while motivation/“yearning” circuits (e.g., nucleus accumbens) are prominently engaged in grief.
Individual differences in oxytocin signaling—particularly receptor density within reward/motivation circuits—help explain variability in the intensity and persistence of yearning during grief.
The Kübler-Ross stages are not universal; grief and depression share symptoms but are distinct processes with different neurobiological underpinnings.
Structured “rational grieving” (time-limited sessions that fully feel attachment while avoiding counterfactual thinking), supported by physiologic tools (enhancing vagal tone, stabilizing diurnal cortisol via morning light, prioritizing sleep/NSDR), promotes adaptive grieving and may reduce risk for complicated grief.
Clinical Insight
Effective grieving preserves the felt attachment while deliberately remapping space and time predictions; interventions that enhance vagal tone and normalize diurnal cortisol can facilitate this adaptive neuroplastic transition and help prevent complicated grief.
Actionable Takeaway
Schedule a daily 10–20 minute “rational grieving” session: intentionally feel your attachment to the deceased while actively avoiding counterfactual (“what if”) thoughts; before starting, perform 2–3 minutes of slow, exhale-emphasized breathing to increase vagal tone and stability during the session.
43. This Week in Cardiology
May 29 2026 This Week in Cardiology
Published: 2026-05-29
URL: Listen Here
Summary
This episode highlights major advances and practice nuances: durable LDL lowering via PCSK9 base editing in early-phase testing, modest absolute event reduction with evolocumab in higher-risk non-MI patients (including those post-PCI), and consistent superiority of tirzepatide over semaglutide-dominant care for glycemic and weight outcomes. It also underscores arrhythmia patterns in cardiac amyloidosis that favor pacing and anticoagulation strategies over ICDs, and reviews ongoing debate surrounding new lipid guidelines.
Key Takeaways
In vivo base-editing of hepatic PCSK9 (VERVE-102) in patients with HeFH/premature CAD produced dose-dependent, durable LDL-C reductions of ~44–62% at up to 1 year in a phase 1 study, with mostly mild, transient infusion-related events; long-term safety and off-target risks remain unknown.
VESALIUS-CV prior-PCI subgroup: evolocumab reduced 3-point MACE by ~30% (driven by nonfatal MI) versus placebo in higher-risk patients, with modest absolute risk reduction and no proven mortality benefit; comparable LDL-C targets may be achieved with high-intensity statins ± ezetimibe in many cases.
SURPASS-Early: tirzepatide outperformed intensified conventional care (predominantly semaglutide) over 2 years, achieving larger HbA1c reductions, higher rates of normoglycemia, and greater weight and waist reductions, with expected GI adverse effects and low discontinuation.
ExCALIBUR ILR study in cardiac amyloidosis showed frequent conduction disease requiring pacing (17%) and new, largely silent AF (28%), especially in ATTR; sustained VT occurred mainly in AL, and terminal rhythms were often PEA—supporting emphasis on pacing and anticoagulation over prophylactic ICDs.
Debate continues around the 2026 ACC/AHA lipid guideline regarding complexity, reliance on non-RCT data, risk estimation (PREVENT vs PCE), and conflicts of interest; the writing group issued a rebuttal.
Clinical Insight
In cardiac amyloidosis—particularly ATTR—the predominant arrhythmic threats are conduction disease and silent atrial fibrillation rather than malignant VT/VF, so clinical strategy should prioritize surveillance for heart block and timely anticoagulation over prophylactic ICD implantation.
Actionable Takeaway
When starting incretin-based therapy for adults with type 2 diabetes and obesity, consider tirzepatide as first-line to maximize HbA1c and weight reduction benefits, accounting for tolerability, availability, and coverage.
44. The Human Upgrade: Biohacking for Longevity & Performance
NASCAR Death, Steroid Olympics, Genetic Age Truth, and Gut Depression... : 1475
Published: 2026-05-29
URL: Listen Here
Summary
This episode highlights inflammation as a unifying theme across mental health, aging biology, and acute infectious deterioration, while also discussing transparency in enhanced athletics and the sizable genetic contribution to lifespan. It encourages clinicians to adopt biomarker-guided care—especially IL-6 and CRP—in depression and aging risk, and to act urgently on sepsis warning signs.
Key Takeaways
Open ‘Enhanced Games’ showcased transparent performance enhancement; despite declared drug use, records did not fall as expected, prompting data-driven questions about what truly drives elite performance.
Severe pneumonia can progress rapidly to sepsis—even in fit individuals—making recognition of red flags (worsening breathing, confusion, rapid decline, disproportionate illness severity) and urgent hospital evaluation critical.
Mouse research implicates hypothalamic Menin as a central regulator of aging; restoring Menin improved memory and lifespan, suggesting neuroinflammation control, deep sleep, and glycemic stability may support brain ‘aging control room’ function.
A small pilot trial of IL-6 blockade (tocilizumab) in difficult-to-treat depression showed higher remission versus placebo, reinforcing that immune-driven inflammation can underlie mood disorders and warrant biomarker-guided evaluation.
A Science report argues human lifespan is ~50% heritable after removing extrinsic deaths, supporting personalized longevity strategies grounded in an individual’s genetic architecture rather than population averages.
Clinical Insight
Inflammation is a cross-cutting driver of pathology—from depression to brain aging to sepsis risk—so physicians should integrate inflammatory biomarkers (e.g., hs-CRP, IL-6) into assessments, particularly for treatment-resistant depression and patients with accelerated cognitive decline, while maintaining high vigilance for sepsis in rapidly worsening infections.
Actionable Takeaway
For patients with treatment-resistant depression, add an inflammatory panel (at minimum hs-CRP and IL-6) to the workup and document a baseline to guide targeted management if elevations are found.
45. The Human Upgrade: Biohacking for Longevity & Performance
Brain Fog Starts in Your Feet (Scientifically Proven) : 1476
Published: 2026-05-31
URL: Listen Here
Summary
This episode proposes that brain fog may start ‘from the feet’ via impaired venous return and blunted sensory feedback caused by sedentary living and cushioned footwear. It recommends barefoot/minimal-shoe exposure and targeted foot/calf strengthening to improve cerebral perfusion and autonomic balance, potentially enhancing cognitive clarity. The content is largely mechanistic and anecdotal; no specific studies or clinical guidelines are cited in the discussion.
Key Takeaways
The episode argues that brain fog can originate from reduced lower-extremity circulation—especially diminished calf “muscle pump” activity from sedentary behavior and restrictive/cushioned footwear—leading to decreased cerebral perfusion and cognitive dullness.
Feet provide rich sensory input; thick, cushioned shoes may dampen proprioception, potentially increasing low-level sympathetic arousal and diverting resources from executive function and focus.
Strengthening and mobilizing the feet and activating the calves may improve venous return and sensory signaling, which could enhance mental clarity even without primary brain pathology.
Suggested interventions include barefoot or minimal-footwear time on varied terrain and simple drills (toe splay, object pickups with toes, single-leg balance), plus calf raises, uphill walking, and movement breaks to engage the calf pump.
Workups for nonspecific brain fog should consider peripheral contributors (deconditioning, prolonged sitting, footwear effects) alongside sleep, stress, nutrition, and central neurologic causes.
Clinical Insight
In patients reporting nonspecific ‘brain fog,’ assess and address peripheral circulatory and proprioceptive factors—sedentary time, footwear that restricts foot mechanics, venous pooling/orthostatic symptoms—because small decrements in cerebral blood flow and altered afferent input may meaningfully affect cognition even when structural brain disease is absent.
Actionable Takeaway
Advise patients with brain-fog complaints who sit for long periods to take 5-minute movement breaks each hour (brisk walk or 2–3 sets of 10–15 standing calf raises) and add 5–10 minutes/day of foot-intrinsic and balance work (toe spreads, towel-scrunches or picking up objects with toes, single-leg stance); consider brief, safe barefoot time at home on varied textures and reassess symptoms over 2–4 weeks.
46. The Peter Attia Drive
#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements
Published: 2026-06-01
URL: Listen Here
Summary
This episode reviews sleep pharmacology through a mechanistic lens, distinguishing sedation from physiologic sleep and urging clinicians to match therapy to specific drivers of insomnia after establishing behavioral foundations. It critically appraises benzodiazepines and Z‑drugs, highlights the architecture‑sparing profile and emerging neurodegenerative implications of DORAs, endorses low‑dose trazodone for increasing deep sleep, clarifies melatonin’s role in circadian alignment, and cautions about antihistamines and variable‑quality supplements.
Key Takeaways
Most insomnia stems from disruption in one or more of four drivers—sleep pressure, circadian timing, hyperarousal, and sleep architecture—so evaluation and treatment should be mechanism-targeted, with CBT‑I and sleep hygiene as the foundation after ruling out OSA, restless legs syndrome, and mood/anxiety disorders.
Sedation is not physiologic sleep: many hypnotics flatten sleep architecture (reducing slow‑wave and REM), so matching drug pharmacokinetics and mechanism to the patient’s specific problem (onset vs maintenance vs early awakening vs non‑restorative sleep) is critical.
Benzodiazepines and Z‑drugs can reduce sleep latency but carry risks of dependence, cognitive/motor impairment, complex sleep behaviors (FDA 2019 boxed warning for Z‑drugs), and anterograde amnesia that can mask poor sleep; use the lowest effective dose for the shortest duration if used at all.
Dual orexin receptor antagonists (DORAs) reduce wake drive rather than forcing sedation, generally preserve sleep architecture, improve sleep efficiency, and have lower abuse potential; early animal and small human data suggest possible reductions in CSF amyloid/tau, but neuroprotective use remains investigational.
Trazodone (low dose) increases slow‑wave (N3) sleep and is a reasonable longer‑term option when tolerated; melatonin is a circadian timing signal (best for jet lag/phase shifts, timed 1–3 hours pre‑bed, modest dosing), first‑generation antihistamines should be short‑term only due to anticholinergic burden, and evidence for common supplements is mixed with significant quality‑control variability.
Clinical Insight
Treat insomnia by first identifying the dominant driver(s) and prioritizing CBT‑I and circadian/homeostatic alignment; when medication is indicated, favor agents that preserve sleep architecture (e.g., DORAs, low‑dose trazodone) and avoid chronic benzodiazepine, Z‑drug, or anticholinergic antihistamine use due to harms that can ultimately worsen sleep and safety.
Actionable Takeaway
Adopt a brief four‑driver checklist (sleep pressure, circadian timing, hyperarousal, sleep architecture) for every insomnia visit; document the predominant driver(s) and, if sleep‑maintenance insomnia with hyperarousal persists after CBT‑I/hygiene, consider a DORA (start at the lowest dose, counsel on next‑day impairment and rare narcolepsy‑like events) rather than a Z‑drug or benzodiazepine.
47. Huberman Lab
Peptides: The Science, Uses & Safety | Dr. Abud Bakri
Published: 2026-06-01
URL: Listen Here
Summary
This episode provides a master class on peptide medicine—clarifying mechanisms, evidence quality, safety, and regulation across GLP‑1s, BPC‑157, growth hormone secretagogues, thymic/bioregulatory peptides, and GHK‑Cu. It offers clinicians a practical framework to differentiate well‑validated tools from experimental compounds, emphasizing careful titration, sourcing, monitoring, and patient counseling. Note: several topics rely on limited human data or non‑U.S. literature, which constrains definitive clinical recommendations.
Key Takeaways
Peptides span two practical categories for clinicians: agents with known receptors and robust human data (e.g., GLP‑1 receptor agonists) versus agents lacking identified receptors and/or human evidence (e.g., BPC‑157), a distinction that should drive risk–benefit, sourcing, and regulatory decisions.
GLP‑1/GIP/glucagon agonists (semaglutide, tirzepatide, retatrutide) deliver unprecedented, clinically meaningful weight loss when titrated carefully and paired with nutrition, hydration, and resistance training; mood and motivation changes may reflect dose, under‑nutrition/electrolyte issues, or central effects and warrant monitoring.
BPC‑157 shows broad tissue‑repair and GI‑protective effects in animals but has minimal human data (small UC enema trials); safety signals (e.g., angiogenesis/hemangiomas) and sourcing quality are unresolved, and gray‑market variability is substantial.
Growth hormone secretagogues (e.g., tesamorelin, ipamorelin, MK‑677) can raise IGF‑1 and aid recovery/sleep but may worsen insulin resistance, alter sleep architecture, and affect prostate metrics—supporting cautious, monitored, and time‑limited use if pursued.
Thymic and bioregulatory peptides (e.g., thymosin‑α1, TB‑500; epitalon and pinealon/EDR) are intriguing for immunity, circadian biology, and skin/brain effects; early studies (e.g., TRIIM) and Russian literature suggest promise, but rigorous randomized human trials and standardized biomarkers (e.g., lymphocyte:monocyte ratio) are needed. Topical GHK‑Cu has the best human support among aesthetics‑focused peptides.
Clinical Insight
Use an evidence‑tiered framework: prioritize FDA‑approved, receptor‑defined peptides with strong human data (e.g., GLP‑1 RAs) and treat non‑approved or non‑receptor peptides (e.g., BPC‑157, many bioregulators) as investigational—avoid gray‑market sources, discuss unknowns explicitly, and monitor targeted labs when any peptide affecting endocrine, immune, or repair pathways is considered.
Actionable Takeaway
Begin tracking the lymphocyte‑to‑monocyte ratio (LMR) from routine CBC‑diff in adults with frequent infections or post‑viral fatigue; if LMR is low, address fundamentals (sleep/circadian light, diet including adequate protein and zinc, stress), consider immunology referral, and avoid prescribing non‑approved thymic peptides outside clinical trials.
Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:
Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website
From Insights to Action
Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:
Personalized Medical AI Chatbot
Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.
Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.
It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.
👉 Deploy your Medical AI Chatbot today and take control of your health narrative
Premium Longevity Program
For people who know their most valuable asset is their health.
This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.
👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.